Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist developed by Altimmune (now acquired by Novo Nordisk’s obesity pipeline network). Unlike single-target GLP-1 agonists such as semaglutide, pemvidutide simultaneously activates both the GLP-1 receptor and the glucagon receptor, aiming to combine appetite suppression with glucagon-mediated increases in energy expenditure and hepatic fat reduction.[1][2]

Pemvidutide has generated significant clinical interest through phase 2 trials in both obesity and metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH), with the Lancet publishing results from the IMPACT trial in December 2025. The dual-agonist approach positions pemvidutide alongside tirzepatide (GIP/GLP-1) and retatrutide (GLP-1/GIP/glucagon) as part of the multi-receptor agonist class.[1][3]

Compound Profile

What Does Pemvidutide Actually Do?

Pemvidutide combines two pharmacological actions through dual receptor activation. GLP-1R agonism suppresses appetite and improves glycaemic control (the mechanism shared with semaglutide), while glucagon receptor agonism increases hepatic lipid oxidation, energy expenditure, and preferentially reduces liver fat.[1][2]

The IMPACT phase 2b trial published in The Lancet demonstrated that pemvidutide achieved significant weight loss and improvements in hepatic steatosis in patients with MASH. At 24 weeks, pemvidutide produced clinically meaningful reductions in liver fat content and improvements in markers of liver fibrosis — addressing a disease where effective pharmacological treatments remain limited.[1]

How Pemvidutide Works

Pemvidutide’s dual mechanism creates complementary metabolic effects through two distinct receptor pathways:[2][3]

GLP-1 receptor activation: Reduces appetite through hypothalamic signalling, enhances glucose-dependent insulin secretion, slows gastric emptying, and promotes satiety. This component drives the weight loss and glycaemic improvement seen with all GLP-1 agonists.

Glucagon receptor activation: Stimulates hepatic fatty acid oxidation and ketogenesis, increases resting energy expenditure, and promotes liver fat mobilisation. Glucagon’s catabolic effects on liver fat complement GLP-1’s appetite-suppressive effects, potentially producing greater hepatic steatosis reduction than GLP-1 agonism alone.

The rationale for dual agonism is that glucagon’s metabolic effects — increased energy expenditure and liver fat reduction — address aspects of metabolic disease that GLP-1 agonism alone does not optimally target. The challenge is balancing glucagon’s hyperglycaemic effects with GLP-1’s glucose-lowering activity, which pemvidutide achieves through calibrated receptor activation ratios.

Pemvidutide’s once-weekly injection profile is achieved through fatty acid acylation (similar to semaglutide’s albumin-binding approach), extending plasma half-life through reversible albumin binding.

Appetite & Weight Management Context

Pemvidutide’s clinical data positions it within the appetite and weight management research landscape as a next-generation multi-agonist. Phase 2 obesity trial data showed significant weight loss, with the dual GLP-1/glucagon mechanism theoretically offering advantages over pure GLP-1 agonism through additional energy expenditure stimulation.[2][4]

A key question is whether the glucagon component provides meaningful additional weight loss beyond what GLP-1 agonism alone achieves. Early data suggests the contribution is present but modest compared to the appetite-suppressive effects of GLP-1R activation. The primary differentiator may be body composition — glucagon’s preferential mobilisation of liver and visceral fat could produce metabolically superior weight loss even at similar total weight reduction.[1]

Compare with semaglutide (GLP-1 only), tirzepatide (GIP/GLP-1), and retatrutide (triple GLP-1/GIP/glucagon), or see the Appetite & Weight Management goal page.

Metabolic Health / Insulin Sensitivity Context

The MASH indication places pemvidutide squarely within the metabolic health context. MASH — the inflammatory stage of fatty liver disease — has no approved pharmacological cure, making effective treatments a major unmet medical need. Pemvidutide’s glucagon-mediated liver fat reduction directly targets the pathological process driving MASH progression.[1][3]

The Lancet-published IMPACT trial demonstrated significant reductions in hepatic steatosis and improvements in fibrosis markers at 24 weeks. A GRADE-assessed meta-analysis confirmed pemvidutide’s efficacy and safety profile in the MASH population, providing systematic evidence synthesis beyond individual trial results.[5]

Glycaemic effects reflect the balanced dual agonism — GLP-1’s glucose-lowering activity offsets glucagon’s hyperglycaemic tendency, resulting in net-neutral to mildly improved glucose control in most patients. See the Metabolic Health goal page for broader context.

Fat Loss & Recomp Context

Pemvidutide’s glucagon component adds a fat loss-relevant dimension beyond pure appetite suppression. Glucagon receptor activation stimulates hepatic lipid oxidation and increases resting energy expenditure, potentially producing preferential fat mass reduction compared to agents that reduce weight primarily through caloric restriction.[2]

Concerns about muscle loss during pharmacological weight loss have been raised across the GLP-1 agonist class. Whether pemvidutide’s dual mechanism produces a more favourable fat-to-lean mass loss ratio compared to GLP-1-only agents is an active research question. The increased energy expenditure from glucagon agonism theoretically favours fat oxidation, but clinical body composition data is limited.[6]

See the Fat Loss & Recomp goal page for broader context.

Pemvidutide Benefits

• Dual mechanism: Simultaneous GLP-1 and glucagon receptor activation provides complementary metabolic effects — appetite suppression plus increased energy expenditure and liver fat reduction.[1][2]
• Lancet-published MASH data: Phase 2b results in MASH showed significant hepatic steatosis reduction and fibrosis improvement — addressing a major unmet medical need.[1][3]
• Weekly injection: Once-weekly subcutaneous dosing provides convenient administration comparable to semaglutide.
• Preferential liver fat reduction: Glucagon-mediated hepatic lipid oxidation may produce metabolically superior outcomes compared to weight loss from appetite suppression alone.[2]
• Energy expenditure increase: Glucagon agonism stimulates resting energy expenditure, a mechanism not present in pure GLP-1 agonists.[2]

Pemvidutide Side Effects

Phase 2 clinical trial data provides safety characterisation:

• Gastrointestinal effects: Nausea, vomiting, and diarrhoea were the most common adverse events — consistent with the GLP-1 agonist class. Rates were generally manageable with dose titration.
• Appetite reduction: Significant appetite suppression, while therapeutically desirable, can be excessive at higher doses.
• Glycaemic effects: The glucagon component’s hyperglycaemic tendency is partially offset by GLP-1’s glucose-lowering effect, but monitoring is needed in diabetic patients.
• Heart rate effects: Small increases in heart rate have been observed, consistent with GLP-1 agonist class effects.
• Limited long-term data: Phase 2 trial durations (24 weeks) do not capture potential long-term safety signals.

Half-Life

Pemvidutide has a plasma half-life supporting once-weekly subcutaneous injection, achieved through fatty acid acylation that promotes reversible albumin binding in circulation. This pharmacokinetic approach is analogous to the half-life extension strategy used in semaglutide. Exact half-life values from pharmacokinetic studies have been characterised in the clinical pharmacokinetics literature.[7]

Limits of Current Evidence

• No phase 3 data: While phase 2b results are promising and Lancet-published, phase 3 trials are needed for regulatory submission and to confirm findings in larger populations.
• Short trial duration: 24-week data does not capture durability of effect, potential for treatment resistance, or long-term safety.
• Body composition data limited: Whether the glucagon component truly produces superior fat-to-lean mass loss ratios requires more detailed body composition studies.[6]
• Competitive landscape pressure: Pemvidutide enters a rapidly expanding market with semaglutide, tirzepatide, and retatrutide — distinguishing itself commercially requires clear clinical advantages.
• MASH endpoint debate: Surrogate endpoints (liver fat, fibrosis markers) used in phase 2 MASH trials may not predict hard clinical outcomes (cirrhosis prevention, liver transplant reduction).

Verdict

Pemvidutide occupies a compelling position in the multi-agonist peptide landscape — a dual GLP-1/glucagon agonist with Lancet-published phase 2b data in one of medicine’s most significant unmet needs (MASH). The glucagon component provides a pharmacologically rational addition to GLP-1 agonism, targeting liver fat metabolism and energy expenditure in ways that single-target agents do not.

The clinical evidence supports both weight management and hepatic steatosis applications, with the MASH indication arguably offering the clearest competitive differentiation. Whether pemvidutide can secure a distinct clinical niche against the formidable competition from tirzepatide and retatrutide depends on phase 3 results, particularly in MASH-specific hard endpoints and body composition outcomes.

FAQ

What is pemvidutide?

Pemvidutide (ALT-801) is a dual GLP-1/glucagon receptor agonist — a once-weekly injectable peptide that simultaneously activates both the GLP-1 receptor (reducing appetite) and the glucagon receptor (increasing energy expenditure and liver fat oxidation). It has completed phase 2b trials in obesity and MASH.

How does pemvidutide differ from semaglutide?

Semaglutide activates only the GLP-1 receptor. Pemvidutide activates both GLP-1 and glucagon receptors. The glucagon component adds hepatic fat reduction and increased energy expenditure — effects not produced by GLP-1 agonism alone. Both are once-weekly injectable peptides.

What is pemvidutide used for?

Pemvidutide is being investigated for obesity/weight management and for metabolic dysfunction-associated steatohepatitis (MASH/NASH). The Lancet-published IMPACT trial focused on the MASH indication, showing significant liver fat reduction and fibrosis improvement. Pemvidutide is not yet approved for any indication.

What are pemvidutide side effects?

The most common side effects in clinical trials were gastrointestinal (nausea, vomiting, diarrhoea) — consistent with GLP-1 agonist class effects. Small heart rate increases and appetite reduction were also observed. Long-term safety beyond 24 weeks has not been characterised.

Is pemvidutide approved?

No. Pemvidutide has completed phase 2b clinical trials but has not been approved by any regulatory agency. Phase 3 trials would be needed for regulatory submission. Results from the IMPACT trial were published in The Lancet in December 2025.

How does pemvidutide compare to tirzepatide?

Tirzepatide (Mounjaro/Zepbound) is a dual GIP/GLP-1 agonist, while pemvidutide is a dual GLP-1/glucagon agonist. They use different second receptors: tirzepatide adds GIP (which enhances insulin secretion), pemvidutide adds glucagon (which increases energy expenditure and liver fat oxidation). Tirzepatide is approved and has more extensive clinical data.

References

1. Noureddin M, et al. Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results of a randomised, double-blind, phase 2b trial. Lancet. 2025. PMID: 41237796
2. Anderson SL, et al. Emerging concepts in obesity management: focus on pemvidutide. Drugs Context. 2025. PMID: 40734920
3. Tacke F, et al. The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial. Lancet. 2025. PMID: 41352959
4. Harrison SA, et al. Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study. J Hepatol. 2025. PMID: 39002641
5. Rajab I, et al. Efficacy and safety of pemvidutide in MASH: a GRADE-assessed meta-analysis of randomized controlled trials. Naunyn Schmiedebergs Arch Pharmacol. 2026. PMID: 41879841
6. von Haehling S, et al. Muscle Loss in Obesity Therapy as a Therapeutic Target: Trial Design and Endpoints for Regulatory Discussions. J Cachexia Sarcopenia Muscle. 2025. PMID: 41362110
7. Nordell P, et al. Systemic Pharmacokinetic Principles of Therapeutic Peptides. Clin Pharmacokinet. 2026. PMID: 41661442

Survodutide (also known by its development code BI 456906) is a GLP-1/glucagon dual agonist peptide designed by Zealand Pharma and developed clinically by Boehringer Ingelheim. Unlike single-target GLP-1 receptor agonists such as semaglutide or liraglutide, the survodutide peptide simultaneously activates both the glucagon-like peptide-1 receptor (GLP-1R) and the glucagon receptor (GCGR).

This dual-receptor approach is specifically intended to address conditions where appetite suppression alone is insufficient. The glucagon component of survodutide targets the liver directly, promoting hepatic fat oxidation and increasing energy expenditure — mechanisms that are particularly relevant for MASLD (metabolic dysfunction-associated steatotic liver disease) and its progressive form, MASH.

The survodutide Boehringer development programme has progressed rapidly, receiving FDA Breakthrough Therapy Designation for MASH. The compound is administered as a once-weekly subcutaneous injection with an estimated half-life of approximately 60–70 hours.

Compound Profile

Mechanism of Action

Survodutide’s mechanism relies on the coordinated activation of two receptor systems, each contributing distinct metabolic effects.

GLP-1 receptor activation drives appetite suppression, slowed gastric emptying, and improved glucose-dependent insulin secretion. These are the same pathways targeted by established GLP-1 receptor agonists used in appetite and weight management.

Glucagon receptor activation adds a differentiated dimension. Glucagon signalling in the liver increases hepatic fat oxidation, promotes glycogenolysis, and elevates resting energy expenditure. Preclinical pharmacology studies demonstrated that the survodutide glucagon component is essential for the compound’s superior weight loss and metabolic effects beyond what GLP-1 activation alone achieves. A 2025 preclinical study confirmed that hepatic GCGR activation is specifically required for the enhanced weight loss and metabolic improvements observed with this GLP-1 glucagon dual agonist class.

This dual-agonist design positions survodutide as more than a weight loss drug. The glucagon-mediated liver effects make it a potentially first-in-class treatment for MASH — a condition characterised by fat accumulation, inflammation, and fibrosis in the liver for which limited pharmacological options currently exist.

Zealand Pharma engineered the peptide backbone to achieve balanced potency at both receptors, while Boehringer Ingelheim has led the clinical development programme. Biomarker and pharmacological profiling studies have characterised survodutide’s receptor engagement, confirming robust dual activation at clinically relevant exposures.

MASLD / MASH Clinical Evidence

The most compelling clinical data for survodutide comes from its Phase 2 trial in MASH, published in the New England Journal of Medicine in 2024.

In this randomised, placebo-controlled study, participants with biopsy-confirmed MASH and liver fibrosis (stages F1–F3) received survodutide at escalating doses for 48 weeks. The results were striking:

• 83% resolution of steatohepatitis without worsening of fibrosis at the highest dose group — compared to 18.2% in the placebo arm
• Significant fibrosis improvement by at least one stage in a substantial proportion of treated participants
• Marked reductions in liver fat content as measured by MRI-derived proton density fat fraction
• Dose-dependent improvements in liver biomarkers including ALT and AST

These survodutide MASLD results represent some of the most robust liver-specific outcomes seen with any incretin-based therapy to date. The survodutide liver benefits are thought to derive primarily from the glucagon receptor component, which directly promotes hepatic fat oxidation — an effect that pure GLP-1 agonists do not replicate as effectively.

A separate Phase 1 study evaluated survodutide in patients with compensated cirrhosis (Child-Pugh A), confirming acceptable tolerability and pharmacokinetic profiles in this more advanced liver disease population.

Weight Loss Data

Survodutide weight loss data from Phase 2 trials has demonstrated clinically meaningful results across multiple study populations.

In the pivotal Phase 2 obesity trial published in The Lancet Diabetes & Endocrinology, adults with obesity (BMI ≥30, or ≥27 with comorbidities) received survodutide at various doses for 46 weeks:

• The highest dose group achieved mean weight loss of up to 18.7% of baseline body weight
• Weight reductions were dose-dependent and progressive throughout the treatment period
• Survodutide demonstrated weight loss comparable to or exceeding that observed with open-label semaglutide 2.4 mg in the same study

In a separate Phase 2 trial in people with type 2 diabetes, survodutide produced significant HbA1c reductions alongside meaningful weight loss, with dose-response effects observed across treatment arms. The dual mechanism — combining appetite suppression through GLP-1R with increased energy expenditure through GCGR — likely contributes to the magnitude of weight reduction achieved.

A 2025 systematic review and meta-analysis pooling data across survodutide trials confirmed consistent efficacy on both glycaemic control and weight loss in adults, with effect sizes that position it competitively among next-generation incretin-based therapies for fat loss.

Metabolic Effects

Beyond weight and liver outcomes, survodutide has demonstrated broad metabolic benefits in clinical trials:

Glycaemic control: In the Phase 2 type 2 diabetes study, survodutide GLP-1 and glucagon co-activation produced dose-dependent reductions in HbA1c, with the highest doses achieving reductions that were clinically comparable to established GLP-1 agonists. The dual mechanism may offer an advantage in patients with both obesity and diabetes, where glucagon’s effects on hepatic glucose output are balanced by the insulin-sensitising effects of weight loss and GLP-1R activation.

Lipid metabolism: Clinical data indicates improvements in triglyceride levels and other lipid parameters, consistent with the expected effects of both weight reduction and enhanced hepatic fat oxidation mediated by glucagon signalling.

Insulin sensitivity: Weight loss of the magnitude seen with survodutide (up to 18.7%) would be expected to produce meaningful improvements in insulin sensitivity, though dedicated insulin clamp studies have not been published at the time of writing.

Cardiovascular biomarkers: The SYNCHRONIZE cardiovascular outcomes trial (CVOT) has been designed to evaluate survodutide’s effects on major adverse cardiovascular events in people with obesity, reflecting the expectation that its metabolic benefits may translate to cardiovascular risk reduction.

Safety and Side Effects

The survodutide side effects profile observed across Phase 1 and Phase 2 trials is broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events representing the most common adverse effects.

Common side effects reported in clinical trials:

• Nausea — the most frequently reported adverse event, typically mild to moderate and most common during dose escalation
• Vomiting — also most prevalent during the titration phase
• Diarrhoea — occurring at rates similar to other GLP-1-based therapies
• Decreased appetite — generally considered a therapeutic effect rather than a side effect
• Constipation — reported by a minority of participants

Tolerability considerations: The Phase 1 programme established that a gradual dose-escalation strategy meaningfully reduces the incidence and severity of gastrointestinal side effects. Most adverse events were transient and diminished with continued treatment.

Glucagon-specific safety signals: Because survodutide activates the glucagon receptor, there is theoretical concern about hyperglycaemia. However, clinical data suggests that the GLP-1 component effectively counterbalances glucagon’s glycaemic effects, and no clinically significant hyperglycaemia has been reported in trials. Mild, transient increases in heart rate were observed in some dose groups, consistent with GLP-1 receptor agonist pharmacology.

The Phase 1 study in Japanese men with overweight/obesity confirmed a similar safety profile, supporting the generalisability of these findings across populations.

SYNCHRONIZE Phase 3 Programme

The survodutide Phase 3 clinical development programme, branded SYNCHRONIZE, represents one of the most ambitious Phase 3 programmes in the incretin space. It includes multiple pivotal trials:

SYNCHRONIZE-1: Phase 3 trial evaluating survodutide for weight management in adults with obesity without type 2 diabetes.

SYNCHRONIZE-2: Phase 3 trial in adults with obesity and type 2 diabetes. Published baseline characteristics confirm a large, multinational study population designed to support regulatory approval.

SYNCHRONIZE-CVOT: A cardiovascular outcomes trial assessing whether survodutide reduces major adverse cardiovascular events in people with established cardiovascular disease and obesity. The trial design, published in JACC: Heart Failure, reflects the regulatory expectation for cardiovascular safety and efficacy data.

SYNCHRONIZE-MASH: Phase 3 trials in MASH, building on the strong Phase 2 results. The FDA’s Breakthrough Therapy Designation for the MASH indication underscores the unmet medical need and the strength of existing clinical evidence.

If successful, the SYNCHRONIZE programme could position survodutide Boehringer Ingelheim as a first-in-class treatment for MASH and a competitive option for obesity — potentially differentiating it from the crowded GLP-1 agonist field through its liver-focused mechanism.

Research Limitations

While the survodutide evidence base is promising, several important limitations should be acknowledged:

• No Phase 3 efficacy data published yet: The strongest clinical evidence comes from Phase 2 trials. Phase 3 results from the SYNCHRONIZE programme are anticipated but not yet available. Phase 2 effect sizes do not always replicate in larger Phase 3 populations.
• Limited long-term safety data: The longest published treatment duration is 48 weeks. Long-term safety beyond one year — including effects on bone density, lean mass preservation, and potential thyroid signals — remains unknown.
• Histological endpoints require confirmation: The MASH Phase 2 trial used liver biopsy endpoints, which are the gold standard but involve inherent sampling variability. Phase 3 confirmation with larger sample sizes is needed.
• Glucagon-specific risks are not fully characterised: The long-term metabolic consequences of chronic glucagon receptor activation — including potential effects on amino acid metabolism, hepatic protein synthesis, and adrenal function — require further investigation.
• Head-to-head comparisons are limited: Direct comparisons with semaglutide exist only in a Phase 2 type 2 diabetes trial. No head-to-head data exists against tirzepatide, retatrutide, or resmetirom (the only currently approved MASH treatment).
• Population generalisability: Most trial participants were from Western populations. The Phase 1 Japanese study provides some cross-population data, but broader diversity is needed.

Verdict

Survodutide is one of the most promising peptides in the metabolic disease pipeline. Its GLP-1/glucagon dual agonist mechanism offers a differentiated approach that goes beyond appetite suppression — directly targeting the liver through glucagon receptor activation to promote hepatic fat clearance and increase energy expenditure.

The Phase 2 MASH results, with 83% steatohepatitis resolution, represent potentially best-in-class liver outcomes among incretin-based therapies. Combined with weight loss of up to 18.7% and meaningful glycaemic improvements, survodutide addresses the interconnected pathology of obesity, type 2 diabetes, and fatty liver disease.

However, evidence confidence remains moderate. Phase 3 data from the SYNCHRONIZE programme will be the decisive factor in determining whether survodutide’s Phase 2 promise translates to regulatory approval and clinical use. The compound’s safety profile appears manageable but requires longer-term characterisation, and head-to-head trials against established competitors would strengthen its positioning.

For researchers and clinicians tracking the next generation of metabolic therapies, survodutide — alongside retatrutide and tirzepatide — represents a meaningful evolution beyond first-generation GLP-1 agonists, with the liver-focused mechanism being its most compelling differentiator.

FAQ

What is survodutide?

Survodutide (BI 456906) is a GLP-1/glucagon dual agonist peptide developed by Boehringer Ingelheim in partnership with Zealand Pharma. It activates both the GLP-1 receptor and the glucagon receptor, combining appetite suppression with increased hepatic fat oxidation and energy expenditure. It is currently in Phase 3 clinical trials for obesity and MASH.

How does survodutide differ from semaglutide?

While semaglutide is a pure GLP-1 receptor agonist, survodutide is a GLP-1 glucagon dual agonist that also activates the glucagon receptor. This additional glucagon component promotes direct hepatic fat burning and increases resting energy expenditure — mechanisms not present with semaglutide. This makes survodutide particularly relevant for liver diseases like MASLD and MASH.

What are the main survodutide side effects?

The most commonly reported survodutide side effects in clinical trials are gastrointestinal in nature: nausea, vomiting, diarrhoea, and decreased appetite. These are generally mild to moderate, most common during dose escalation, and tend to diminish with continued treatment. The safety profile is broadly similar to other GLP-1-based therapies.

What were the survodutide MASH trial results?

In the Phase 2 MASH trial published in the New England Journal of Medicine, survodutide achieved 83% resolution of steatohepatitis at the highest dose, compared to 18.2% with placebo. Significant improvements in fibrosis stage and liver fat content were also observed, representing some of the strongest liver-specific results for any incretin-based therapy.

How much weight loss does survodutide produce?

In the Phase 2 obesity trial, participants receiving the highest dose of survodutide achieved mean weight loss of up to 18.7% of baseline body weight over 46 weeks. Weight loss was dose-dependent and comparable to or exceeding open-label semaglutide 2.4 mg in the same study.

What is the SYNCHRONIZE programme?

SYNCHRONIZE is the survodutide Phase 3 clinical development programme run by Boehringer Ingelheim. It includes separate pivotal trials for obesity (with and without type 2 diabetes), MASH, and a cardiovascular outcomes trial. These trials will determine whether survodutide receives regulatory approval.

Is survodutide approved for clinical use?

No. As of early 2026, survodutide remains an investigational compound in Phase 3 trials. It has received FDA Breakthrough Therapy Designation for the MASH indication, but no regulatory approvals have been granted. Phase 3 results are anticipated in the coming years.

What is the survodutide half-life?

Survodutide has an estimated half-life of approximately 60–70 hours, which supports once-weekly subcutaneous administration. This pharmacokinetic profile was established through Phase 1 clinical studies in both Western and Japanese populations.

How does survodutide compare to retatrutide?

Retatrutide is a triple agonist (GLP-1/GIP/glucagon) while survodutide is a dual agonist (GLP-1/glucagon only). Retatrutide has shown greater weight loss in Phase 2 (over 24%), but survodutide is further advanced in clinical development and has stronger published liver-specific data. Both share the glucagon component that differentiates them from GLP-1/GIP agonists like tirzepatide.

Who developed survodutide?

The survodutide peptide backbone was designed by Zealand Pharma, a Danish biotechnology company specialising in peptide therapeutics. Boehringer Ingelheim, a German pharmaceutical company, leads the clinical development programme and holds the global rights. The Boehringer Ingelheim survodutide programme is one of the largest in the company’s metabolic disease portfolio.

References

1. Zimmermann T et al. “BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy.” Mol Metab, 2022. PubMed
2. Jungnik A et al. “Phase I studies of the safety, tolerability, pharmacokinetics and pharmacodynamics of the dual glucagon receptor/glucagon-like peptide-1 receptor agonist BI 456906.” Diabetes Obes Metab, 2023. PubMed
3. Blüher M et al. “Dose-response effects on HbA1c and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial.” Diabetologia, 2024. PubMed
4. le Roux CW et al. “Glucagon and GLP-1 receptor dual agonist survodutide for obesity: a randomised, double-blind, placebo-controlled, dose-finding phase 2 trial.” Lancet Diabetes Endocrinol, 2024. PubMed
5. Sanyal AJ et al. “A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis.” N Engl J Med, 2024. PubMed
6. Lawitz EJ et al. “Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis.” J Hepatol, 2024. PubMed
7. Thomas L et al. “The dual GCGR/GLP-1R agonist survodutide: Biomarkers and pharmacological profiling for clinical candidate selection.” Diabetes Obes Metab, 2024. PubMed
8. Kosiborod MN et al. “Survodutide for the Treatment of Obesity: Rationale and Design of the SYNCHRONIZE Cardiovascular Outcomes Trial.” JACC Heart Fail, 2024. PubMed
9. Wharton S et al. “Baseline characteristics in the SYNCHRONIZE-2 randomized phase 3 trial of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for obesity in people with type 2 diabetes.” Diabetes Obes Metab, 2026. PubMed
10. Xiao YJ et al. “Efficacy and safety of survodutide on glycemic control and weight loss in adults: A systematic review and meta-analysis.” Diabetes Obes Metab, 2025. PubMed

Mazdutide (also known by its development codes IBI362 and LY3305677) is a GLP-1/glucagon dual receptor agonist — an engineered peptide that simultaneously activates two key metabolic receptors involved in appetite regulation, energy expenditure, and glucose control. Originally developed by Mazdutide Innovent Biologics in China, this mazdutide peptide became the world’s first GLP-1 glucagon dual agonist to receive regulatory approval for obesity when China’s National Medical Products Administration (NMPA) granted marketing authorisation in July 2025.

The compound is based on the structure of oxyntomodulin, a naturally occurring gut hormone that activates both GLP-1 and glucagon receptors. By engineering a synthetic analogue with improved pharmacokinetic properties — including a half-life of approximately 130 hours (~5.4 days) — researchers created a once-weekly subcutaneous injection suitable for chronic weight management. Eli Lilly licensed the ex-China development rights in a 2022 deal worth over $200 million upfront, signalling substantial pharmaceutical industry interest in this dual-agonist approach.

Mazdutide sits within a rapidly expanding class of multi-receptor agonists alongside compounds like tirzepatide (GLP-1/GIP dual agonist) and retatrutide (GLP-1/GIP/glucagon triple agonist). What distinguishes mazdutide is its specific combination of GLP-1 and glucagon receptor activation — a pairing that research suggests may offer unique advantages for both appetite and weight management and hepatic fat reduction.

Compound Profile

Mechanism of Action

As a GLP-1 glucagon dual agonist, mazdutide engages two distinct receptor pathways that contribute to its metabolic effects through complementary mechanisms.

GLP-1 Receptor Activation

The GLP-1 receptor agonist component of mazdutide mirrors the well-characterised effects of established compounds like semaglutide and liraglutide. Activation of the GLP-1 receptor in the brain’s hypothalamus and brainstem reduces appetite and increases satiety signalling. In the pancreas, GLP-1 receptor activation enhances glucose-dependent insulin secretion and suppresses glucagon release, contributing to improved glycaemic control. The mazdutide GLP-1 component also slows gastric emptying, which may further extend post-meal satiety.

Glucagon Receptor Activation

The mazdutide glucagon receptor component is what fundamentally differentiates this compound from pure GLP-1 receptor agonists. Glucagon receptor activation in the liver promotes glycogenolysis and gluconeogenesis, but its metabolic effects extend well beyond glucose production. Research indicates that glucagon receptor activation increases hepatic lipid oxidation and energy expenditure — essentially encouraging the body to burn more energy at rest. This thermogenic effect adds a caloric expenditure dimension to weight loss that pure GLP-1 RAs lack.

Additionally, glucagon receptor signalling appears to directly promote hepatic fat mobilisation, which may explain the emerging data on liver fat reduction with mazdutide. Preclinical and clinical evidence suggests that the glucagon component drives fatty acid oxidation in the liver, reducing hepatic steatosis through a mechanism distinct from simple caloric restriction.

The dual-receptor approach creates what researchers describe as a synergistic metabolic effect: GLP-1 receptor activation reduces caloric intake through appetite suppression, while glucagon receptor activation increases caloric expenditure through enhanced thermogenesis and lipid oxidation. This complementary pairing may explain why clinical data shows weight loss with mazdutide alongside favourable metabolic outcomes for metabolic health and insulin sensitivity.

Clinical Evidence

The mazdutide clinical programme includes two major Phase 3 trial series — GLORY (obesity/overweight) and DREAMS (type 2 diabetes) — alongside earlier Phase 1 and Phase 2 studies. Combined, these trials form a substantial evidence base that supported Chinese regulatory approval and underpin ongoing global development.

Phase 1 and Phase 2 Foundations

Early clinical development began with a Phase 1b randomised controlled trial in Chinese patients with type 2 diabetes, which established the safety and pharmacokinetic profile of the compound (then designated IBI362). This study demonstrated dose-dependent reductions in HbA1c and body weight, providing proof-of-concept for dual GLP-1/glucagon receptor activation in humans.

A pivotal Phase 2 randomised controlled trial in Chinese adults with overweight or obesity (n=610) showed that mazdutide produced clinically meaningful weight loss across multiple dose levels over 24 weeks. Mean body weight reductions ranged from approximately 5% to 11% depending on dose, with the highest doses approaching efficacy levels typically seen with established GLP-1 RAs over longer treatment periods. A parallel Phase 2 trial in type 2 diabetes demonstrated significant HbA1c reductions alongside weight loss.

GLORY Trials (Obesity/Overweight)

The mazdutide phase 3 GLORY-1 trial, published in the New England Journal of Medicine in 2025, was the pivotal study supporting obesity approval. This multicentre, randomised, double-blind trial enrolled Chinese adults with obesity or overweight (with at least one weight-related comorbidity) and evaluated mazdutide at escalating doses over 48 weeks. The trial demonstrated substantial weight reduction compared to placebo, with statistically significant differences across all dose groups.

DREAMS Trials (Type 2 Diabetes)

The DREAMS trial programme evaluated mazdutide specifically in adults with type 2 diabetes. DREAMS-1, published in Nature, demonstrated that mazdutide significantly reduced HbA1c compared to placebo in Chinese adults with T2D, achieving clinically meaningful glycaemic improvements alongside body weight reduction. DREAMS-2, also published in Nature, compared mazdutide directly to dulaglutide and showed superior efficacy on both HbA1c reduction and weight loss endpoints. A DREAMS-3 trial comparing mazdutide head-to-head with semaglutide is currently underway.

Weight Loss Data

Mazdutide weight loss data from the Phase 3 GLORY-1 trial represents the most robust evidence for this compound’s efficacy in weight management. At 48 weeks, participants receiving the highest dose of mazdutide achieved mean body weight reductions of approximately 15% from baseline — a clinically significant result that positioned the compound competitively within the incretin-based weight loss landscape.

To contextualise these findings: in the GLORY-1 trial, the placebo-subtracted weight loss at 48 weeks was substantial, with a significant proportion of participants achieving ≥10% and ≥15% body weight reduction thresholds. These response rates are clinically relevant because evidence suggests that 10-15% weight loss produces meaningful improvements in obesity-related comorbidities including cardiovascular risk factors, obstructive sleep apnoea, and joint pain.

Earlier Phase 2 data in Chinese adults with overweight or obesity showed dose-dependent weight loss over 24 weeks, with higher doses producing greater reductions. The Phase 1 high-dose trial conducted by Eli Lilly in a broader (non-Chinese) population also demonstrated meaningful weight reduction, suggesting the effects may be generalisable beyond the Chinese cohort.

It is worth noting that the magnitude of mazdutide weight loss observed in the GLORY trials — while impressive — was assessed exclusively in Chinese adults, and cross-ethnic extrapolation should be approached with caution. Global Phase 3 trials currently underway will provide critical data on efficacy in Western populations. Research in the area of fat loss and body recomposition continues to evolve with these multi-receptor agonists.

Metabolic & Glycaemic Effects

Beyond weight loss, mazdutide demonstrates significant effects on glycaemic control and broader metabolic parameters — effects that appear partly attributable to its unique dual-receptor mechanism.

HbA1c Reduction

In the DREAMS-1 Phase 3 trial, mazdutide produced clinically meaningful reductions in HbA1c in adults with type 2 diabetes. The magnitude of glycaemic improvement was substantial, meeting pre-specified non-inferiority and superiority endpoints. In DREAMS-2, mazdutide demonstrated superior HbA1c reduction compared to dulaglutide, an established GLP-1 RA widely used in clinical practice.

The Phase 2 trial in type 2 diabetes published in Diabetes Care showed dose-dependent HbA1c reductions of up to approximately 1.5 percentage points, with the highest dose groups achieving the greatest glycaemic improvements. Importantly, these reductions occurred alongside significant weight loss, suggesting synergistic benefits for patients with both diabetes and obesity.

Insulin Sensitivity and Metabolic Markers

Clinical data indicates that mazdutide improves several metabolic markers beyond glycaemic control. Evidence from the trial programme suggests improvements in fasting glucose, fasting insulin, and markers of insulin resistance. The glucagon receptor component may contribute to these effects through enhanced hepatic lipid oxidation, which research suggests can improve hepatic insulin sensitivity by reducing intrahepatic triglyceride content.

Lipid profile improvements have also been observed, including reductions in triglycerides and total cholesterol. While lipid effects are common across GLP-1 RA class drugs, the glucagon component of mazdutide may enhance these benefits through direct hepatic lipid mobilisation pathways.

Liver Fat & MASLD Research

One of the most scientifically compelling aspects of mazdutide relates to its potential for reducing hepatic steatosis — the hallmark of metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD). The glucagon receptor agonist component provides a mechanistic rationale for enhanced liver fat reduction compared to pure GLP-1 RAs.

Glucagon signalling in the liver directly promotes fatty acid oxidation, stimulates lipid mobilisation from hepatocytes, and may reduce de novo lipogenesis. These effects, combined with the weight-loss-driven reduction in hepatic fat delivery, create a dual mechanism for addressing hepatic steatosis. Preclinical data consistently shows that GLP-1/glucagon dual agonists produce greater liver fat reduction than equivalent GLP-1-only stimulation.

Clinical evidence for mazdutide’s effects on liver fat is still emerging. Secondary endpoints and exploratory analyses from the GLORY and DREAMS programmes have suggested reductions in liver-related biomarkers, though dedicated liver imaging studies with mazdutide-specific MASLD endpoints are needed to fully characterise this effect. The broader class of GLP-1/glucagon dual agonists — including survodutide from Boehringer Ingelheim — has generated encouraging liver fat reduction data, suggesting a class-level benefit that mazdutide likely shares.

Given the enormous global burden of MASLD and the limited approved pharmacological options, the hepatic effects of the glp-1 glucagon dual agonist class represent a potentially transformative therapeutic avenue. However, more targeted clinical trials are required before definitive conclusions about mazdutide’s MASLD benefits can be drawn.

Safety & Side Effects

The mazdutide side effects profile is broadly consistent with the GLP-1 receptor agonist class, with gastrointestinal events being the most frequently reported adverse effects across all clinical trials.

Common Side Effects

Gastrointestinal adverse events — including nausea, vomiting, diarrhoea, and decreased appetite — were the most commonly reported mazdutide side effects in both the GLORY and DREAMS trials. These events were predominantly mild to moderate in severity and tended to occur during the dose-escalation phase, decreasing in frequency with continued treatment. The incidence of GI adverse events was dose-dependent, with higher doses producing more frequent events.

Discontinuation Rates

In the GLORY-1 Phase 3 trial, the rate of treatment discontinuation due to adverse events was higher in the mazdutide groups compared to placebo, though the overall discontinuation rate was manageable. The majority of discontinuations were related to gastrointestinal intolerance during early dose escalation.

Glucagon-Specific Considerations

The glucagon receptor agonist component introduces theoretical safety considerations that differ from pure GLP-1 RAs. Glucagon is known to promote hepatic glucose output, which raises questions about glycaemic balance — particularly in patients with diabetes. However, clinical data from the DREAMS trials suggests that the GLP-1 component effectively counterbalances any pro-hyperglycaemic effects of glucagon receptor activation, with net improvements in glycaemic control observed across all dose levels.

Heart rate increases have been observed with mazdutide, consistent with findings seen across GLP-1-based therapies. The long-term cardiovascular safety profile remains to be fully established through dedicated cardiovascular outcome trials. No clinically significant signals for pancreatitis, thyroid tumours, or gallbladder-related events beyond background rates have been reported, though post-marketing surveillance and longer-term studies will be important for confirming the safety profile.

Research Limitations

While the evidence base for mazdutide is substantial and growing, several important limitations should be considered when interpreting the available data.

Population specificity: All pivotal Phase 3 trials (GLORY and DREAMS) were conducted exclusively in Chinese adults. East Asian populations may respond differently to incretin-based therapies due to differences in body composition, beta-cell function, and metabolic phenotype. The Eli Lilly high-dose Phase 1 trial included a broader population, but definitive efficacy data in Western cohorts awaits the completion of ongoing global Phase 3 trials.

Duration of evidence: The longest controlled trial data available spans 48 weeks. Obesity and type 2 diabetes are chronic conditions requiring long-term treatment, and the durability of weight loss, safety over years of use, and effects on hard clinical endpoints (cardiovascular events, mortality) remain unknown.

Comparator data gaps: While DREAMS-2 compared mazdutide to dulaglutide and DREAMS-3 is comparing it to semaglutide, there are no head-to-head trials against tirzepatide, survodutide, or retatrutide. Cross-trial comparisons are inherently unreliable due to differences in patient populations, trial design, and endpoints.

Liver fat evidence: While the mechanistic rationale for hepatic benefit is strong, dedicated imaging-based studies with MASLD-specific primary endpoints have not yet been published for mazdutide specifically. Claims about liver fat reduction should be interpreted as preliminary.

Cardiovascular outcomes: No dedicated cardiovascular outcome trial has been completed for mazdutide. While the metabolic improvements observed are likely to be cardioprotective, this has not been confirmed in outcome studies.

Long-term safety: Post-marketing safety data from China is still accumulating. The theoretical risks associated with chronic glucagon receptor stimulation — including effects on hepatic glucose output, bone density, and body composition — require longer-term monitoring.

Verdict

Mazdutide represents a genuinely novel approach to metabolic disease — one of the first compounds to demonstrate that co-activating GLP-1 and glucagon receptors can produce clinically meaningful weight loss and glycaemic improvement with an acceptable safety profile. Its approval in China as the world’s first GLP-1/glucagon dual agonist for obesity marks a significant milestone in the evolution of incretin-based therapeutics.

The clinical evidence is encouraging. Phase 3 data showing approximately 15% weight loss at 48 weeks places mazdutide in competitive territory, while the DREAMS trials confirm robust efficacy in type 2 diabetes. The mechanistic advantage of glucagon receptor activation — enhanced energy expenditure and potential liver fat benefits — distinguishes it from pure GLP-1 RAs and GLP-1/GIP dual agonists like tirzepatide.

However, several caveats temper enthusiasm. The evidence base is currently limited to Chinese populations, and global Phase 3 data will be critical for establishing whether these results translate across ethnic groups. The compound faces intense competition from tirzepatide, semaglutide, retatrutide, and survodutide — each with distinct receptor profiles and varying levels of clinical evidence. Head-to-head comparisons will ultimately determine where mazdutide fits in the treatment hierarchy.

For the research community, mazdutide provides important proof-of-concept that the glp-1 glucagon dual agonist class is clinically viable. Whether the glucagon component delivers meaningful advantages over existing therapies in real-world practice remains an open question that ongoing global trials should help answer.

FAQ

What is mazdutide?

Mazdutide is a GLP-1/glucagon dual receptor agonist — an engineered peptide that activates both the GLP-1 receptor and the glucagon receptor. Based on the structure of oxyntomodulin, this mazdutide peptide was developed by Innovent Biologics and is designed as a once-weekly subcutaneous injection for obesity and type 2 diabetes. It was the first compound in its class to receive regulatory approval for weight management (China, July 2025).

How does mazdutide differ from semaglutide?

While semaglutide is a pure GLP-1 receptor agonist, mazdutide activates both GLP-1 and glucagon receptors. This dual mechanism means mazdutide may promote energy expenditure through the glucagon component in addition to the appetite suppression provided by GLP-1 receptor activation. Research suggests this could offer advantages for liver fat reduction and overall metabolic improvement compared to GLP-1-only approaches.

What weight loss does mazdutide produce?

In the GLORY-1 Phase 3 trial, mazdutide weight loss at 48 weeks reached approximately 15% from baseline at the highest dose level. Earlier Phase 2 data showed dose-dependent weight reductions of 5-11% over 24 weeks. These results are from Chinese populations, and global trial data in Western populations is pending.

What are the main mazdutide side effects?

The most commonly reported mazdutide side effects are gastrointestinal in nature — nausea, vomiting, diarrhoea, and decreased appetite. These are consistent with the GLP-1 receptor agonist class and tend to be most frequent during dose escalation, typically diminishing with continued treatment. Most adverse events were mild to moderate in severity.

Is mazdutide approved for use?

As of 2025, mazdutide has received regulatory approval in China for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. It is not yet approved in the United States, European Union, or other major markets. Eli Lilly holds ex-China development rights and global Phase 3 trials are underway.

What is the difference between mazdutide and tirzepatide?

Mazdutide is a GLP-1/glucagon dual agonist, while tirzepatide is a GLP-1/GIP dual agonist. These are fundamentally different receptor combinations. Tirzepatide has shown greater peak weight loss in trials (~22% vs ~15%), but mazdutide’s glucagon component may provide distinct advantages for energy expenditure and liver fat reduction that GIP receptor activation does not offer.

Who developed mazdutide?

Mazdutide was originally developed by Mazdutide Innovent Biologics, a Chinese biopharmaceutical company. In 2022, Eli Lilly acquired the ex-China development and commercialisation rights in a licensing deal worth over $200 million upfront. Innovent retains rights within China, where the compound has already been approved and launched.

What are the GLORY and DREAMS trials?

The GLORY trials are the mazdutide phase 3 clinical programme for obesity/overweight, with GLORY-1 (published in NEJM) serving as the pivotal approval trial. The DREAMS trials are the Phase 3 programme for type 2 diabetes, with DREAMS-1 and DREAMS-2 (both published in Nature) evaluating mazdutide versus placebo and versus dulaglutide respectively. DREAMS-3 is comparing mazdutide with semaglutide.

Could mazdutide help with liver fat (MASLD/NAFLD)?

Research suggests that mazdutide’s glucagon receptor component may be beneficial for reducing liver fat, as glucagon signalling promotes hepatic fatty acid oxidation. While dedicated MASLD imaging trials for mazdutide are still pending, the broader class of GLP-1/glucagon dual agonists has shown promising liver fat reduction data. This remains an active area of investigation.

How does mazdutide compare to survodutide?

Mazdutide and survodutide (Boehringer Ingelheim) are both GLP-1/glucagon dual agonists, making them the most direct competitors in this class. Survodutide has shown greater peak weight loss in Phase 2 data (~19% vs ~15%), but mazdutide is further along in development — having achieved regulatory approval in China while survodutide remains in Phase 3. The two compounds differ in their receptor potency ratios, which may produce clinically distinct profiles.

References

1. Ji L et al. “Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight.” N Engl J Med, 2025; 392(22):2215-2225. PubMed
2. Zhu D et al. “Mazdutide versus placebo in Chinese adults with type 2 diabetes.” Nature, 2026; 652(8108):174-180. PubMed
3. Guo L et al. “Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes.” Nature, 2026; 652(8108):181-188. PubMed
4. Ji L et al. “A phase 2 randomised controlled trial of mazdutide in Chinese overweight adults or adults with obesity.” Nat Commun, 2023; 14(1):8289. PubMed
5. Zhang B et al. “Efficacy and Safety of Mazdutide in Chinese Patients With Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial.” Diabetes Care, 2024; 47(1):160-168. PubMed
6. Jiang H et al. “A phase 1b randomised controlled trial of a glucagon-like peptide-1 and glucagon receptor dual agonist IBI362 (LY3305677) in Chinese patients with type 2 diabetes.” Nat Commun, 2022; 13(1):3613. PubMed
7. Bhattachar SN et al. “Mazdutide reduces body weight in adults with overweight or obesity: A high-dose Phase 1 trial.” Diabetes Obes Metab, 2025; 27(11):6460-6469. PubMed
8. Shirley M. “Mazdutide: First Approval.” Drugs, 2025; 85(12):1621-1627. PubMed
9. Neff GW. “Shared mechanistic pathways of glucagon signalling: Unlocking its potential for treating obesity, MASLD, and other cardio-kidney-metabolic conditions.” Diabetes Obes Metab, 2025; 27(12):6869-6883. PubMed
10. Luo Y et al. “Mazdutide versus Semaglutide for the treatment of type 2 diabetes and obesity: Rationale, design and baseline data of DREAMS-3 phase 3 trial.” Contemp Clin Trials, 2026; 160:108150. PubMed

Amycretin is a first-in-class unimolecular peptide co-agonist developed by Novo Nordisk that simultaneously activates both the glucagon-like peptide-1 (GLP-1) receptor and amylin receptor from a single molecule. As an amycretin peptide, it represents a genuinely novel approach to appetite and weight management — combining two proven satiety-related signalling pathways into one compound.

What makes amycretin particularly noteworthy is its oral formulation. While most GLP-1-based therapies — including semaglutide (Wegovy/Ozempic) and tirzepatide (Mounjaro) — require subcutaneous injection, oral amycretin is delivered as a simple tablet. This positions it as a potential breakthrough for individuals who prefer non-injectable treatment options.

Unlike orforglipron, which is also orally available but classified as a small-molecule GLP-1 agonist, amycretin is a true peptide. Its peptide backbone allows it to engage amylin receptors with an affinity that small molecules have struggled to replicate — a structural distinction with meaningful pharmacological implications.

Compound Profile

Mechanism of Action

Amycretin’s dual mechanism centres on the simultaneous activation of two distinct receptor systems involved in appetite regulation, glucose homeostasis, and energy balance.

GLP-1 Receptor Activation

The GLP-1 receptor component functions similarly to established incretin therapies like semaglutide and liraglutide. By activating GLP-1 receptors in the pancreas, gut, and brain, amycretin promotes insulin secretion in a glucose-dependent manner, slows gastric emptying, and reduces appetite through central nervous system signalling.

Amylin Receptor Activation

The amylin receptor component adds a complementary appetite-suppressing pathway. Amylin — a hormone naturally co-secreted with insulin from pancreatic beta cells — acts on the area postrema and other brainstem regions to reduce food intake, slow gastric emptying, and suppress post-meal glucagon release. By incorporating amylin receptor agonism, amycretin accesses satiety circuits that GLP-1 alone does not fully engage.

Preclinical research in rodent models indicates that this unimolecular GLP-1/amylin co-agonist approach produces weight loss and glycaemic improvements that exceed those achieved by either GLP-1 or amylin agonism alone. Kuhre et al. (2025) demonstrated in mice and rats that amycretin produced superior body weight reduction and metabolic improvements compared with semaglutide monotherapy, suggesting a genuinely synergistic interaction between the two receptor pathways rather than merely additive effects.

Clinical Evidence

The clinical programme for amycretin centres on the REDEFINE trials conducted by Amycretin Novo Nordisk‘s development team. To date, Phase 1 and Phase 2 data have been published, with results that have generated considerable interest in the obesity pharmacotherapy field.

Phase 1 Trial

The first-in-human Phase 1 trial, published in The Lancet by Gasiorek et al. (2025), was a double-blind, randomised, placebo-controlled study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of amycretin in healthy adults. The trial established that amycretin was generally well tolerated, with a pharmacokinetic profile supporting once-weekly administration. The estimated half-life of approximately 46 hours supports less frequent dosing schedules.

Phase 1b/2a Subcutaneous Trial

A parallel Phase 1b/2a study (Dahl et al., 2025) investigated subcutaneous amycretin in adults with overweight or obesity. Participants receiving the highest subcutaneous doses achieved substantial body weight reductions, confirming that dual GLP-1/amylin receptor engagement translates into meaningful clinical weight loss.

REDEFINE 1 — Phase 2 Oral Trial

The amycretin phase 2 REDEFINE 1 trial represents the most clinically significant dataset to date. This randomised, placebo-controlled study evaluated oral amycretin in adults with obesity or overweight with at least one weight-related comorbidity. Over 36 weeks, participants receiving oral amycretin achieved up to 13.1% body weight loss — a remarkable figure for an oral formulation that requires no injection.

To put the amycretin results in context: oral semaglutide (Rybelsus) in the OASIS 1 trial delivered approximately 15.1% weight loss at 68 weeks at its highest dose, but that required nearly twice the treatment duration. The amycretin weight loss achieved at 36 weeks suggests that longer-term studies could yield even more substantial reductions as dose escalation continues.

Weight Loss Research Context

The amycretin weight loss data from REDEFINE 1 sits within a rapidly evolving landscape of incretin-based obesity therapies. Several key comparisons help contextualise the significance of these findings.

Injectable semaglutide 2.4 mg (Wegovy) produces approximately 15–17% weight loss at 68 weeks. Tirzepatide, a dual GIP/GLP-1 agonist, has demonstrated up to 22.5% weight loss at 72 weeks. CagriSema — Novo Nordisk’s injectable combination of cagrilintide (an amylin analogue) and semaglutide — has shown approximately 22.7% weight loss at 68 weeks in Phase 3 trials.

What distinguishes the amycretin data is the route of administration. Achieving 13.1% weight loss at just 36 weeks via an oral tablet — without any injection — represents a meaningful advance. As clinical development progresses into Phase 3 with longer treatment durations and optimised dose titration, the full weight loss potential of oral amycretin remains to be defined.

Research also suggests that the dual GLP-1/amylin mechanism may offer advantages beyond raw weight loss numbers. The amylin pathway appears to preferentially reduce visceral adipose tissue and may support greater preservation of lean mass during weight loss — findings that, while primarily from preclinical data, could have significant implications for body composition outcomes in the context of fat loss and recomposition.

Metabolic Effects

Beyond weight reduction, amycretin demonstrates promising effects on markers of metabolic health and insulin sensitivity. The dual receptor mechanism positions it to address multiple aspects of metabolic dysfunction simultaneously.

Glycaemic Control

Preclinical studies by Kuhre et al. (2025) demonstrated that amycretin produced superior glycaemic control compared with semaglutide monotherapy in rodent models of metabolic dysfunction. The GLP-1 component enhances glucose-dependent insulin secretion, while the amylin component suppresses inappropriate glucagon release — together providing more comprehensive blood glucose regulation than either mechanism alone.

Insulin Sensitivity

Weight loss itself improves insulin sensitivity, and the degree of weight reduction observed with amycretin in Phase 2 trials would be expected to meaningfully improve insulin resistance. Additionally, the amylin receptor pathway has been associated with direct improvements in hepatic insulin sensitivity in preclinical models, though this remains to be confirmed in dedicated human metabolic studies.

Lipid Metabolism

GLP-1 receptor agonists as a class have demonstrated improvements in lipid profiles, including reductions in triglycerides and increases in HDL cholesterol. Research suggests that dual GLP-1/amylin agonism may amplify these effects, though dedicated cardiovascular outcome and lipid studies for amycretin have not yet been completed.

Oral Bioavailability & Formulation

One of the most significant challenges in peptide therapeutics is achieving adequate oral bioavailability. Peptides are typically degraded by gastrointestinal enzymes and poorly absorbed across the intestinal epithelium — which is why most GLP-1-based therapies require injection.

Novo Nordisk’s existing oral semaglutide formulation (Rybelsus) uses SNAC (sodium N-[8-(2-hydroxybenzoyl)amino]caprylate) as an absorption enhancer, but this approach has limitations including relatively low bioavailability and strict fasting requirements. The specific oral delivery technology used for oral amycretin has not been fully disclosed, but the Phase 2 data suggest that Novo Nordisk has achieved clinically relevant systemic exposure through oral administration.

The ability to deliver a peptide co-agonist orally — rather than as a small molecule mimic — is pharmacologically significant. Peptide structures can engage receptor binding sites, particularly at the amylin receptor, with greater specificity and affinity than small molecules. This is a key distinction between amycretin and small-molecule oral GLP-1 agonists like orforglipron, which lack amylin receptor activity entirely.

From a practical standpoint, an oral tablet formulation could dramatically improve treatment accessibility and adherence. Research consistently demonstrates that many individuals with obesity prefer oral medications over injectable alternatives, and removing the injection barrier could expand the reach of effective pharmacological weight management considerably.

Safety & Side Effects

Understanding the safety profile is essential context for any investigational compound. The available data on amycretin side effects comes primarily from Phase 1 and Phase 2 clinical trials, which provide useful but limited safety information compared with the larger datasets generated by Phase 3 studies and post-marketing surveillance.

Gastrointestinal Effects

Consistent with the broader GLP-1 receptor agonist class, the most commonly reported amycretin side effects are gastrointestinal in nature. Nausea, vomiting, and diarrhoea were the most frequent adverse events reported in clinical trials. These effects were generally mild to moderate in severity, typically occurred during dose escalation phases, and tended to diminish with continued treatment.

Tolerability Profile

The Phase 1 trial by Gasiorek et al. (2025) reported that amycretin was generally well tolerated across the dose ranges tested. Discontinuation rates due to adverse events appeared comparable to those observed with other incretin-based therapies, though direct head-to-head safety comparisons have not been conducted.

Class-Level Considerations

As a GLP-1 receptor agonist, amycretin carries theoretical risks common to the broader class, including potential effects on gallbladder function, pancreatic enzyme levels, and heart rate. The amylin receptor component introduces additional theoretical considerations, though pramlintide (the only approved amylin analogue) has an established safety profile that provides some reassurance. Long-term safety data from Phase 3 trials will be essential to fully characterise the risk profile of this dual-mechanism compound.

No signal of increased pancreatitis or thyroid C-cell tumours has emerged from clinical trials to date, though these studies were not powered to detect rare events.

Research Limitations

While the amycretin data to date are encouraging, several important limitations warrant consideration.

Limited clinical dataset: The evidence base rests primarily on Phase 1 and Phase 2 trials. These studies involve relatively small participant numbers and short durations compared with the Phase 3 programmes that typically support regulatory approval. The amycretin phase 2 REDEFINE 1 trial lasted 36 weeks — meaningful, but shorter than the 52–72 week durations common in pivotal obesity trials.

No Phase 3 data yet: Phase 3 trials are expected to begin in 2026, but until they report, the full efficacy and safety profile of amycretin remains uncertain. Phase 3 studies will involve larger, more diverse populations and longer treatment periods that may reveal efficacy ceiling effects or safety signals not apparent in earlier trials.

No cardiovascular outcomes data: GLP-1 receptor agonists have demonstrated cardiovascular benefits in dedicated outcomes trials (SUSTAIN-6, SELECT), but no such data exist for amycretin. Whether the added amylin component enhances, diminishes, or has no effect on cardiovascular outcomes remains unknown.

Weight regain after discontinuation: A well-established limitation of incretin-based therapies is weight regain upon treatment cessation. Whether amycretin’s dual mechanism offers any advantage in weight maintenance has not been studied.

Undisclosed molecular details: Novo Nordisk has not fully disclosed amycretin’s molecular structure, absorption enhancement technology, or detailed pharmacokinetic parameters. This limits independent scientific scrutiny of the compound’s properties.

Verdict

Amycretin represents one of the most interesting compounds in the current obesity pharmacotherapy pipeline. As the first oral unimolecular GLP-1/amylin co-agonist, it occupies a unique position — combining dual receptor engagement (previously only achievable through injection) with the convenience of a daily tablet.

The Phase 2 amycretin results — up to 13.1% weight loss at 36 weeks via oral administration — are clinically meaningful and suggest genuine synergy between the GLP-1 and amylin receptor pathways. The preclinical evidence of superiority over semaglutide monotherapy adds mechanistic credibility to the clinical findings.

However, the evidence confidence remains moderate. Until Phase 3 data from the REDEFINE programme confirm these results in larger populations over longer durations, and until safety is characterised more comprehensively, amycretin should be understood as a promising but unproven investigational compound. Amycretin Novo Nordisk‘s development programme is expected to advance into Phase 3 in 2026, which should provide the definitive data needed to assess its place alongside — or potentially ahead of — existing GLP-1-based therapies.

For the broader field, amycretin’s success would validate two important principles: that oral delivery of complex peptides is pharmacologically viable, and that dual GLP-1/amylin agonism from a single molecule can produce clinically superior outcomes to either mechanism alone.

FAQ

What is amycretin?

Amycretin is a first-in-class unimolecular peptide co-agonist developed by Novo Nordisk that simultaneously activates both GLP-1 and amylin receptors. It is being developed as an oral tablet for the treatment of obesity, representing the first oral GLP-1/amylin co-agonist in clinical development.

How does amycretin differ from semaglutide?

While semaglutide acts solely on GLP-1 receptors, amycretin engages both GLP-1 and amylin receptors from a single molecule. Preclinical evidence suggests this dual mechanism produces superior weight loss and glycaemic control compared with GLP-1 agonism alone. Additionally, amycretin is being developed primarily as an oral formulation, whereas semaglutide’s most effective weight-loss formulation (Wegovy) requires injection.

What weight loss has amycretin shown in clinical trials?

In the Phase 2 REDEFINE 1 trial, oral amycretin produced up to 13.1% body weight loss at 36 weeks compared with placebo. This is notable because it was achieved with an oral tablet rather than an injection, and at a relatively early stage of dose optimisation.

Is amycretin a peptide or a small molecule?

Amycretin is a genuine peptide — a modified peptide sequence engineered for oral bioavailability and dual receptor activity. This distinguishes it from small-molecule oral GLP-1 agonists like orforglipron, which cannot engage amylin receptors due to their non-peptide structure.

What are the main amycretin side effects?

The most commonly reported amycretin side effects in clinical trials were gastrointestinal — primarily nausea, vomiting, and diarrhoea. These are consistent with the broader GLP-1 agonist class and were generally mild to moderate, often resolving during continued treatment. Long-term safety data from Phase 3 trials are still awaited.

When will amycretin be available?

Amycretin is currently an investigational compound. Phase 3 clinical trials are expected to commence in 2026. If successful, regulatory submissions and potential approval would follow — likely placing any market availability several years away. It is not currently approved for any indication.

How does amycretin compare with CagriSema?

CagriSema combines two separate injectable peptides — cagrilintide (amylin analogue) and semaglutide (GLP-1 agonist) — in a single injection. Amycretin achieves dual GLP-1/amylin activity from a single molecule delivered orally. While CagriSema has shown greater absolute weight loss in Phase 3 (approximately 22.7%), amycretin’s oral convenience and single-molecule design represent a different value proposition.

What is the REDEFINE clinical programme?

REDEFINE is Novo Nordisk’s clinical trial programme for amycretin. REDEFINE 1 was the Phase 2 study evaluating oral amycretin for weight loss in adults with obesity or overweight. The programme is expected to expand into Phase 3 trials to further evaluate efficacy, safety, and long-term outcomes.

Can amycretin be taken orally?

Yes — oral delivery is one of amycretin’s key differentiators. The Phase 2 REDEFINE 1 trial specifically evaluated oral amycretin as a daily tablet. Novo Nordisk has also studied a subcutaneous injectable formulation, but the oral route is considered the primary development pathway for weight management.

What is the evidence confidence for amycretin?

Evidence confidence is currently rated as moderate. The Phase 2 data are strong and published in high-impact peer-reviewed journals, but no Phase 3 results are available yet. As larger and longer studies report, the evidence base will strengthen considerably. Researchers should interpret the current data as promising but preliminary.

References

1. Gasiorek A et al. “Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial.” Lancet, 2025; 406(10499):135-148. PubMed
2. Dahl K et al. “Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study.” Lancet, 2025; 406(10499):149-162. PubMed
3. Khoo B, Tan TM. “GLP-1 and amylin receptor multiagonism with amycretin for obesity management.” Lancet, 2025; 406(10499):104-106. PubMed
4. Kuhre RE et al. “The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats.” EBioMedicine, 2025; 118:105862. PubMed
5. Fu L et al. “Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives.” Metabolism, 2026; 179:156594. PubMed
6. Bailey CJ, Flatt PR, Conlon JM. “Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes.” Peptides, 2026; 196:171480. PubMed
7. Bailey CJ, Flatt PR, Conlon JM. “Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities.” Peptides, 2025; 187:171380. PubMed
8. Son JW et al. “Novel GLP-1-based Medications for Type 2 Diabetes and Obesity.” Endocrine Reviews, 2026; 47(2):159-177. PubMed
9. Rejili M et al. “Amylin receptors as therapeutic targets in obesity: Emerging peptide-based strategies.” Vascular Pharmacology, 2026; 162:107563. PubMed
10. Nauck MA et al. “Glucagon-like receptor agonists and next-generation incretin-based medications: metabolic, cardiovascular, and renal benefits.” Lancet, 2026; 407(10531):892-908. PubMed

Cagrilintide is a synthetic, long-acting amylin analog designed to mimic and extend the physiological actions of native human amylin. In healthy physiology, amylin is co-released with insulin after meals and acts on brainstem receptors — particularly the area postrema and nucleus tractus solitarius — to promote satiety, slow gastric emptying, and suppress post-meal glucagon secretion.[1][5]

The problem with native amylin is its extremely short half-life (approximately 13 minutes) and a tendency to aggregate into amyloid fibrils, making it impractical as a therapeutic agent. Cagrilintide overcomes both limitations through strategic modifications: the attachment of a C18 fatty diacid chain via a glutamic acid linker enables reversible albumin binding, dramatically extending its circulating half-life to approximately 160–195 hours and supporting once-weekly subcutaneous administration.[1][6]

The compound was previously known by its research code AM833 during early development. It activates both the calcitonin receptor (CTR) and the amylin receptor subtypes (AMY1, AMY2, AMY3), which are heterodimers of the calcitonin receptor with receptor activity-modifying proteins (RAMPs).[2] This receptor pharmacology distinguishes cagrilintide from GLP-1 based therapies like semaglutide and tirzepatide, which act on entirely different receptor systems.

Compound Profile

Mechanism of Action

Understanding the cagrilintide mechanism of action requires appreciating how amylin signalling differs from — and complements — the incretin pathway.

Central appetite regulation. Cagrilintide acts as a potent long-acting amylin receptor agonist, binding to amylin receptors (AMY1–3) concentrated in the area postrema and hypothalamic nuclei. Activation of these receptors reduces food intake through direct neuronal signalling, independent of the GLP-1 pathway. The area postrema sits outside the blood-brain barrier, allowing circulating cagrilintide direct access to these satiety centres.[2][5]

Calcitonin receptor activation. In addition to amylin receptor subtypes, cagrilintide activates the calcitonin receptor (CTR) itself. In vitro pharmacological profiling confirmed that AM833 (cagrilintide) is a potent agonist at all three AMY receptor subtypes and at CTR, with a preference for AMY1 and AMY3. This dual calcitonin and amylin receptor agonism (DACRA) may contribute to its weight-lowering effects through additional signalling pathways beyond classical amylin action.[2]

Gastric motility. Like native amylin, cagrilintide slows gastric emptying, prolonging nutrient contact with the gastrointestinal mucosa and contributing to post-meal satiety. This effect is mechanistically distinct from, but additive to, the gastric-slowing properties of GLP-1 agonists.[5][9]

Glucagon suppression. Cagrilintide suppresses post-prandial glucagon secretion from pancreatic alpha cells. By reducing inappropriate glucagon release after meals, the compound helps moderate hepatic glucose output — a mechanism relevant to glycaemic control in type 2 diabetes research.[5][7]

The complementary nature of these mechanisms explains the rationale behind CagriSema: cagrilintide engages brainstem amylin pathways while semaglutide engages hypothalamic and peripheral GLP-1 pathways. The two receptor systems converge on overlapping but distinct neuronal populations controlling energy intake and expenditure.[4][9]

CagriSema: Combination Research

CagriSema — the co-administration of cagrilintide 2.4 mg and semaglutide 2.4 mg once weekly — is the centrepiece of Novo Nordisk’s next-generation obesity pipeline and arguably the most significant cagrilintide semaglutide combination programme in metabolic research. The hypothesis: engaging two distinct satiety pathways (amylin + GLP-1) simultaneously should produce greater weight loss than either mechanism alone.

Phase 1b Proof of Concept

The initial pharmacokinetic and pharmacodynamic study (Enebo et al., 2021) demonstrated that concomitant administration of cagrilintide with semaglutide 2.4 mg was well-tolerated and produced additive weight reductions over 20 weeks. Participants receiving the combination achieved significantly greater body weight loss than semaglutide alone, establishing the proof of concept for dual amylin–GLP-1 agonism.[4]

Phase 2 in Type 2 Diabetes

Frias et al. (2023) published a multicentre, randomised, double-blind trial evaluating CagriSema in adults with type 2 diabetes. Over 32 weeks, cagrilintide 2.4 mg co-administered with semaglutide 2.4 mg produced a mean HbA1c reduction of 2.2 percentage points and a mean body weight reduction of 15.6% — substantially exceeding the effects of semaglutide 2.4 mg monotherapy (5.1% weight loss) and cagrilintide 2.4 mg monotherapy (8.1% weight loss) in the same trial.[7]

REDEFINE Phase 3 Programme

The pivotal Phase 3 data arrived in 2025 with two landmark New England Journal of Medicine publications:

REDEFINE 1 (Garvey et al., 2025): In adults with overweight or obesity without type 2 diabetes, CagriSema produced a mean body weight reduction of approximately 22.7% at 68 weeks, compared to approximately 16.2% for semaglutide 2.4 mg alone and 8.0% for cagrilintide 2.4 mg alone. The proportion of participants achieving ≥20% weight loss was substantially higher in the CagriSema arm.[3]

REDEFINE 2 (Davies et al., 2025): In adults with overweight or obesity and type 2 diabetes, CagriSema demonstrated a mean body weight reduction of approximately 15.7% at 68 weeks, compared to approximately 11.0% for semaglutide 2.4 mg alone. Mean HbA1c reductions with CagriSema reached approximately 2.2 percentage points.[8]

These results position CagriSema as potentially the most effective injectable weight management combination studied in Phase 3 trials to date, exceeding the benchmarks set by semaglutide 2.4 mg (STEP trials) and approaching the territory of tirzepatide (SURMOUNT trials).

Weight Loss Clinical Data

Beyond the CagriSema combination, cagrilintide weight loss data from monotherapy trials provides important context for understanding the amylin pathway’s independent contribution.

Phase 2 Monotherapy Trial

Lau et al. (2021) published a 26-week, multicentre, randomised, double-blind Phase 2 trial comparing multiple cagrilintide doses against placebo and liraglutide 3.0 mg as an active comparator in adults with overweight or obesity. Key findings:[6]

• Cagrilintide at the highest tested doses produced mean body weight reductions of 10.8% (4.5 mg) at 26 weeks
• The 2.4 mg dose — the dose carried forward into CagriSema — produced approximately 9.0% weight loss
• Liraglutide 3.0 mg (daily injection) produced 9.0% weight loss in the active comparator arm
• Placebo produced approximately 3.0% weight loss
• Weight loss curves had not plateaued at 26 weeks, suggesting greater reductions with longer treatment

These results established cagrilintide as a viable standalone weight management research compound, with efficacy comparable to liraglutide 3.0 mg but via a once-weekly injection. However, the real significance was its additive potential when combined with GLP-1 agonism — the foundation of the CagriSema programme.

Metabolic Effects Beyond Weight Loss

The metabolic profile of cagrilintide extends beyond body weight reduction, touching several parameters relevant to cardiometabolic research.

Glycaemic control. In participants with type 2 diabetes, CagriSema produced substantial HbA1c reductions (approximately 2.2 percentage points in REDEFINE 2), with a significant proportion reaching HbA1c targets below 7.0% and below 6.5%. Cagrilintide’s glucagon-suppressive properties contribute to post-prandial glucose control independently of the GLP-1 pathway.[7][8]

Cardiovascular biomarkers. The REDEFINE 1 trial showed improvements in blood pressure, waist circumference, and lipid profiles with CagriSema treatment. A pre-specified analysis (Verma et al., 2026) demonstrated clinically meaningful systolic blood pressure reductions in the CagriSema arm, independent of weight loss magnitude.[10]

Insulin sensitivity. Weight loss mediated by cagrilintide — whether alone or in combination — is associated with improvements in insulin sensitivity markers, including fasting insulin and HOMA-IR. These effects are likely secondary to reduced adiposity rather than direct insulin-sensitising action, but they reinforce the metabolic relevance of the amylin pathway.[6][7]

Body composition. While detailed body composition data (DXA-based) from the REDEFINE programme are still emerging, the magnitude of weight loss with CagriSema suggests significant fat mass reduction. Research into the proportion of lean versus fat mass lost will be critical for understanding the compound’s metabolic quality profile.

Side Effects and Safety Profile

The safety profile of cagrilintide has been characterised across Phase 1 through Phase 3 trials, both as monotherapy and in the CagriSema combination.

Gastrointestinal events. The most common adverse events are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are generally mild to moderate in severity, occur primarily during dose escalation, and tend to diminish with continued treatment. In the REDEFINE trials, discontinuation rates due to adverse events were comparable between CagriSema and semaglutide arms.[3][8]

Injection site reactions. As a subcutaneous injection, cagrilintide is associated with mild injection site reactions in a small proportion of study participants. These are typically transient and do not require treatment discontinuation.[6]

Cardiac safety. A dedicated thorough QT study (Gabe et al., 2024) confirmed that cagrilintide at therapeutic and supratherapeutic exposures does not produce clinically relevant QTc prolongation — an important regulatory milestone for any cardiovascular safety evaluation.[9]

Hypoglycaemia. In participants without type 2 diabetes, clinically significant hypoglycaemia has not been a notable finding. In participants with type 2 diabetes receiving concomitant insulin or sulfonylureas, rates of hypoglycaemia are modestly elevated, as would be expected with any weight-lowering agent in this population.[7][8]

Pancreatic and thyroid safety. Like GLP-1 agonists, amylin analogs carry theoretical signals for pancreatitis and thyroid C-cell concerns. Clinical trial data to date have not identified a significant safety signal for pancreatitis with cagrilintide. Long-term post-marketing surveillance data are not yet available as the compound remains investigational.[3][6]

Pharmacokinetics

The pharmacokinetic profile of cagrilintide is engineered for once-weekly administration, achieved through its albumin-binding acylation strategy.[1]

Half-life. Cagrilintide has an elimination half-life of approximately 160–195 hours (roughly 7–8 days), supporting steady-state concentrations with once-weekly subcutaneous injection. This represents a dramatic extension over native amylin’s 13-minute half-life.[1][6]

Albumin binding. The C18 fatty diacid modification enables reversible, high-affinity binding to serum albumin. This albumin depot effect slows renal clearance and proteolytic degradation, maintaining therapeutic exposure throughout the dosing interval. The mechanism is analogous to the acylation strategy used for semaglutide and liraglutide, though the fatty acid and linker structures differ.[1]

Absorption. Following subcutaneous injection, cagrilintide exhibits a slow absorption profile with time to maximum concentration (T_max) of approximately 24–72 hours. Bioavailability is consistent across injection sites (abdomen, thigh, upper arm).[1][6]

Drug interaction potential. In the CagriSema programme, no clinically meaningful pharmacokinetic interactions were observed between cagrilintide and semaglutide when co-administered. Each compound maintains its independent pharmacokinetic profile, supporting the combination approach.[4]

Steady state. Given the approximately one-week half-life, steady-state concentrations are reached after approximately 4–5 weeks of weekly administration. Dose escalation protocols in clinical trials typically span 16 weeks to mitigate gastrointestinal tolerability during the early treatment phase.[3][6]

Amylin Biology and the Rationale for Cagrilintide

To fully appreciate cagrilintide’s therapeutic positioning, it helps to understand the biology of the amylin system it targets.

Amylin (also known as islet amyloid polypeptide, or IAPP) is a 37-amino-acid peptide hormone produced by pancreatic beta cells and co-secreted with insulin in response to nutrient intake. Its physiological roles include:

• Satiety signalling — via amylin receptors in the area postrema, reducing meal size and food intake
• Gastric emptying regulation — slowing nutrient delivery to the small intestine
• Post-prandial glucagon suppression — reducing hepatic glucose output after meals

In obesity and type 2 diabetes, amylin signalling is often impaired. Beta cell dysfunction reduces amylin secretion, and amylin resistance may develop in the central nervous system. This creates a rationale for exogenous amylin replacement or supplementation — the strategy that cagrilintide fulfils as a potent, long-acting amylin analog.[5][9]

The first amylin-based therapy, pramlintide (Symlin), was approved in 2005 but required three daily injections and produced only modest weight effects. Cagrilintide represents the next generation: once-weekly dosing, greater potency, and clinically meaningful weight reduction potential.[5][9]

FAQ

What is cagrilintide?

Cagrilintide is a long-acting synthetic analog of human amylin, a pancreatic hormone involved in satiety and glucose regulation. Developed by Novo Nordisk under the research code AM833, it is designed for once-weekly subcutaneous injection and is currently under investigation in Phase 3 clinical trials for weight management research. It is not approved for clinical use.

How does cagrilintide differ from GLP-1 receptor agonists like semaglutide?

Cagrilintide targets the amylin receptor system in the brainstem, while GLP-1 agonists like semaglutide act on the GLP-1 receptor in the hypothalamus and periphery. These are complementary but mechanistically distinct satiety pathways. This is precisely why the CagriSema combination (cagrilintide + semaglutide) is being studied — to engage both pathways simultaneously for potentially greater effect.

What is CagriSema?

CagriSema is the co-administration of cagrilintide 2.4 mg and semaglutide 2.4 mg, both given once weekly. It is Novo Nordisk’s next-generation combination therapy under investigation in the REDEFINE Phase 3 programme for obesity and type 2 diabetes. The combination targets two distinct hormone pathways (amylin + GLP-1) and has produced weight reductions of approximately 22.7% in Phase 3 trials.

What weight loss has been observed in cagrilintide clinical trials?

In Phase 2 monotherapy, cagrilintide 2.4 mg produced approximately 9% body weight loss at 26 weeks. In the Phase 3 REDEFINE 1 trial, CagriSema produced approximately 22.7% weight loss at 68 weeks, compared to 16.2% for semaglutide 2.4 mg alone. In REDEFINE 2 (type 2 diabetes), CagriSema achieved approximately 15.7% weight loss at 68 weeks. These are investigational data from clinical trials.

What is the mechanism of action of cagrilintide?

Cagrilintide acts as a potent agonist at amylin receptor subtypes (AMY1, AMY2, AMY3) and the calcitonin receptor (CTR). These receptors are concentrated in the area postrema and hypothalamic nuclei, where activation reduces food intake, slows gastric emptying, and suppresses post-prandial glucagon secretion. The compound’s acylation with a C18 fatty diacid enables albumin binding and a half-life of approximately 160–195 hours.

Is cagrilintide approved by the FDA or other regulators?

No. As of early 2026, cagrilintide remains an investigational compound. It is in Phase 3 clinical trials (the REDEFINE programme) for obesity and type 2 diabetes, both as monotherapy and as the CagriSema combination. Regulatory submissions have not yet been completed. All data should be interpreted in a research context only.

What are the main side effects observed in cagrilintide trials?

The most commonly reported adverse events are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are generally mild to moderate, peak during dose escalation, and tend to resolve with continued treatment. A thorough QT study confirmed no clinically relevant cardiac conduction effects. The safety profile is broadly consistent with other peptide-based metabolic compounds.

How does CagriSema compare to tirzepatide for weight loss?

Direct head-to-head comparison data between CagriSema and tirzepatide are not available from randomised trials. In separate Phase 3 programmes, CagriSema produced approximately 22.7% weight loss at 68 weeks (REDEFINE 1), while tirzepatide 15 mg produced approximately 22.5% at 72 weeks (SURMOUNT-1). Cross-trial comparisons have significant limitations due to differences in populations, trial design, and endpoints.

What makes cagrilintide different from pramlintide?

Both are amylin analogs, but cagrilintide represents a generational advance. Pramlintide (Symlin, approved 2005) requires three daily injections and produces only modest weight effects. Cagrilintide’s acylation strategy extends its half-life to ~7 days, enabling once-weekly injection, and its clinical weight loss data substantially exceed those observed with pramlintide.

Is cagrilintide being studied for type 2 diabetes?

Yes. The REDEFINE 2 trial specifically evaluated CagriSema in adults with type 2 diabetes, demonstrating significant HbA1c reductions (approximately 2.2 percentage points) alongside meaningful weight loss. Cagrilintide’s glucagon-suppressive and gastric-emptying effects are relevant to glycaemic control research beyond weight management alone.

References

1. Kruse T, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021;64(15):11183-11194. PMID: 34288673. PubMed.
2. Fletcher MM, et al. AM833 Is a Novel Agonist of Calcitonin Family G Protein-Coupled Receptors: Pharmacological Comparison with Six Selective and Nonselective Agonists. J Pharmacol Exp Ther. 2021;377(3):417-440. PMID: 33727283. PubMed.
3. Garvey WT, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025;393(7):623-635. PMID: 40544433. PubMed.
4. Enebo LB, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management. Lancet. 2021;397(10286):1736-1748. PMID: 33894838. PubMed.
5. Mathiesen DS, et al. Long-acting amylin analogues for the management of obesity. Curr Opin Endocrinol Diabetes Obes. 2022;29(2):183-190. PMID: 35066542. PubMed.
6. Lau DCW, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021;398(10317):2160-2172. PMID: 34798060. PubMed.
7. Frias JP, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023;402(10403):720-730. PMID: 37364590. PubMed.
8. Davies MJ, et al. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. N Engl J Med. 2025;393(7):636-648. PMID: 40544432. PubMed.
9. Gabe MBN, et al. Cagrilintide is not associated with clinically relevant QTc prolongation: A thorough QT study in healthy participants. Diabetes Obes Metab. 2024;26(12):5757-5766. PMID: 39279639. PubMed.
10. Verma S, et al. CagriSema Reduces Blood Pressure in Adults With Overweight or Obesity: REDEFINE 1. Hypertension. 2026;83(2):e30-e40. PMID: 41328546. PubMed.

If your query is what is retatrutide, the practical answer is: retatrutide (LY3437943) is a first-in-class triple hormone receptor agonist — a single molecule that activates GLP-1, GIP, and glucagon receptors simultaneously. It represents the most aggressive multi-receptor approach to obesity and metabolic disease currently in clinical development, and its Phase 2 trial results (published in the New England Journal of Medicine) produced the largest weight reductions ever reported for any anti-obesity medication.[1][2]

Retatrutide was developed by Eli Lilly (the same company behind tirzepatide). While tirzepatide is a dual GIP/GLP-1 agonist, retatrutide adds glucagon receptor activation as a third mechanism — introducing direct metabolic effects including increased energy expenditure, enhanced hepatic fat oxidation, and thermogenesis that go beyond appetite suppression alone.[2][7]

The compound is currently in Phase 3 clinical trials (the TRIUMPH programme) across multiple indications: obesity, type 2 diabetes, obstructive sleep apnoea, and knee osteoarthritis. No GLP-1-class compound has entered Phase 3 with such strong weight loss signals from earlier-phase data.[1][6]

Compound Profile

What Does Retatrutide Actually Do?

Retatrutide produces weight loss and metabolic improvement through coordinated activation of three hormone receptors. The Phase 2 clinical results are unprecedented in the obesity pharmacotherapy field:[1][2]

• Weight loss (Phase 2, obesity): Jastreboff et al. (2023) demonstrated up to 24.2% mean body weight reduction at 48 weeks with retatrutide 12 mg in adults with obesity — the largest weight loss ever reported for any anti-obesity medication in a controlled trial. Published in the New England Journal of Medicine.[1]
• Weight loss in T2D: Rosenstock et al. (2023) showed retatrutide produced up to 16.9% body weight loss in patients with type 2 diabetes, alongside HbA1c reductions of up to 2.0%. Published in The Lancet.[2]
• Liver fat reduction (MASLD): Sanyal et al. (2024) demonstrated that retatrutide reduced liver fat by up to 82.4% from baseline over 48 weeks, with 93% of participants achieving the ≥30% reduction threshold associated with MASLD resolution. Published in Nature Medicine.[3]
• Body composition: Coskun et al. (2025) published a body composition substudy showing retatrutide produced substantial fat mass reduction. Published in Lancet Diabetes & Endocrinology.[5]
• Meta-analysis confirmation: Pasqualotto et al. (2024) conducted a systematic review and meta-analysis confirming retatrutide’s weight and metabolic benefits across available trials.[4]

How Retatrutide Works

Retatrutide’s triple agonist mechanism is what distinguishes it from all currently approved obesity treatments. Each receptor contributes distinct pharmacological effects:[7][8][9]

• GLP-1 receptor activation: reduces appetite through central hypothalamic and brainstem signalling, slows gastric emptying, and enhances glucose-dependent insulin secretion. This is the shared mechanism with semaglutide and liraglutide.[7][9]
• GIP receptor activation: potentiates the GLP-1-mediated appetite reduction and insulin secretion, while potentially improving fat tissue metabolism. This is the shared mechanism with tirzepatide (which is a dual GIP/GLP-1 agonist).[7][8]
• Glucagon receptor activation (unique to retatrutide): this is the critical differentiator. Glucagon receptor agonism increases hepatic fat oxidation, stimulates thermogenesis and energy expenditure, promotes amino acid catabolism, and reduces liver fat. Unlike GLP-1 and GIP (which primarily reduce caloric intake), glucagon receptor activation increases caloric output.[7][8][9]

The engineering insight: retatrutide doesn’t just suppress appetite more effectively — it adds an entirely new metabolic dimension. The glucagon component creates a “push-pull” effect: GLP-1 and GIP reduce energy intake, while glucagon increases energy expenditure. This dual mechanism likely explains the unprecedented weight loss results and the dramatic liver fat reductions seen in the MASLD trial.[1][3][7]

Coskun et al. (2022) published the preclinical discovery and development of LY3437943 in Cell Metabolism, establishing the pharmacological rationale for the triple agonist approach and demonstrating superior weight loss and metabolic improvement versus dual agonism in preclinical models.[7]

Appetite and Weight Management Context

Appetite and weight management is where retatrutide has generated the most attention — and for good reason. The Phase 2 data represents a step-change in what pharmaceutical weight loss can achieve:[1]

• 24.2% mean weight loss at 48 weeks (12 mg dose) — unprecedented for any anti-obesity medication.[1]
• 100% of 12 mg participants lost ≥5% body weight; 83% lost ≥15%; 63% lost ≥20%.[1]
• Weight loss trajectory still descending at 48 weeks — the full plateau had not been reached, suggesting even greater reductions with longer treatment.[1]

For comparison within the incretin agonist class:

• Liraglutide (Saxenda): ~8% mean weight loss
• Semaglutide (Wegovy): ~15-17% mean weight loss
• Tirzepatide (Zepbound): ~20-22% mean weight loss
• Retatrutide: up to 24.2% mean weight loss — and still declining at study end

The honest caveat: these are Phase 2 results. Phase 3 trials (TRIUMPH) are underway and will provide the definitive efficacy and safety data needed for FDA approval. Phase 2 results don’t always replicate exactly in Phase 3, though the consistency across the obesity and T2D cohorts is encouraging. See Retatrutide vs Tirzepatide for the detailed comparison.[1][2][6]

Fat Loss and Body Recomp Context

Fat loss and body recomposition is where retatrutide’s triple agonist mechanism may offer a genuine advantage over dual and single agonists.

• Body composition data: Coskun et al. (2025) published a dedicated body composition substudy in Lancet Diabetes & Endocrinology, examining DEXA-measured changes in fat mass and lean mass with retatrutide in people with type 2 diabetes.[5]
• Glucagon-driven fat oxidation: the glucagon receptor component specifically promotes hepatic and systemic fat oxidation and thermogenesis — mechanisms that target fat mass reduction beyond what appetite suppression alone achieves.[7][8]
• Liver fat reduction: the Sanyal MASLD trial showed up to 82.4% liver fat reduction — a direct demonstration of the glucagon component’s effect on ectopic fat stores. This degree of hepatic fat clearance has not been achieved by any single or dual agonist.[3]

The lean mass question: like all GLP-1-class compounds, retatrutide-induced weight loss includes some lean mass component. Whether the glucagon receptor’s metabolic effects alter the fat-to-lean-mass loss ratio favourably compared to semaglutide or tirzepatide is being evaluated in Phase 3. Resistance exercise remains the most evidence-based strategy for preserving lean mass during pharmacological weight loss.

Metabolic Health and Insulin Sensitivity Context

Metabolic health and insulin sensitivity is retatrutide’s second major clinical domain, with particularly strong signals in liver health and glycaemic control.[2][3]

• Glycaemic control: Rosenstock et al. (2023) demonstrated HbA1c reductions of up to 2.0% in patients with type 2 diabetes — comparable to or exceeding other incretin-based therapies. Nearly all participants on higher doses achieved HbA1c targets.[2]
• MASLD/liver fat clearance: Sanyal et al. (2024) showed 82.4% liver fat reduction and 93% of participants meeting the ≥30% threshold associated with MASLD resolution. This is the strongest liver fat reduction data for any incretin-class compound — a direct result of the glucagon receptor component.[3]
• Insulin sensitivity improvement: the combination of substantial weight loss, visceral/hepatic fat reduction, and direct metabolic receptor activation produces multi-pathway insulin sensitivity improvement.[2][4]
• Cardiometabolic markers: systematic reviews have confirmed improvements across lipid profiles, blood pressure, and inflammatory markers alongside weight and glucose improvements.[4][10]

The liver health finding is clinically significant: MASLD/MASH (formerly NAFLD/NASH) affects approximately 30% of the global population and is becoming the leading cause of liver transplantation. A compound that can reduce liver fat by >80% while also addressing obesity and diabetes could represent a transformative treatment approach for overlapping cardiometabolic conditions.[3]

Retatrutide Benefits

Retatrutide benefits based on available Phase 2 evidence:

• Unprecedented weight loss magnitude: up to 24.2% mean body weight reduction at 48 weeks — the largest for any anti-obesity medication in controlled trials, and still declining at study end.[1]
• Triple receptor mechanism: unique glucagon receptor component adds energy expenditure and fat oxidation pathways beyond appetite suppression, targeting fat mass through both intake reduction and output increase.[7][8]
• Extraordinary liver fat reduction: up to 82.4% liver fat clearance in the MASLD trial — the strongest hepatic fat reduction of any incretin-class compound.[3]
• Robust glycaemic improvement: HbA1c reductions of up to 2.0% in patients with type 2 diabetes.[2]
• Once-weekly dosing: consistent with other modern incretin agonists, supporting treatment adherence.[1][2]
• Multi-indication potential: Phase 3 TRIUMPH programme spans obesity, T2D, OSA, and osteoarthritis — the broadest indication pipeline of any single incretin agonist.[6]
• Consistent efficacy across cohorts: weight loss and metabolic improvement demonstrated in both obesity and T2D populations, meta-analysis confirmed.[1][2][4]

Important framing: all current retatrutide benefits data is from Phase 2 trials. While the results are exceptionally promising, FDA approval and full safety characterisation require Phase 3 completion. The TRIUMPH programme is expected to report results over the coming years.[6]

Retatrutide Side Effects

For retatrutide side effects intent (search volume: 6,600), the safety profile is based on Phase 2 data with hundreds of participants, not yet the thousands typical of Phase 3:[1][2][11]

• Gastrointestinal effects (most common): nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 receptor agonist class. In the NEJM Phase 2 trial, GI events were generally mild to moderate and most common during dose escalation. Incidence was dose-dependent.[1]
• Decreased appetite: reported frequently, though this is more of an intended pharmacological effect than a side effect per se.[1][2]
• Injection site reactions: generally mild.[1]
• Heart rate increase: small mean increases in heart rate observed, consistent with other GLP-1 agonists.[1][2]
• Glucagon-specific considerations: the glucagon receptor component theoretically increases hepatic glucose output, which could counteract the glucose-lowering effects in some contexts. In practice, the Phase 2 T2D trial showed net glycaemic improvement, suggesting the GLP-1/GIP components compensate effectively.[2][7]

What we don’t know yet:

• Long-term safety: the longest Phase 2 exposure is 48 weeks. Multi-year safety data will come from Phase 3 (TRIUMPH).[6]
• Cardiovascular outcomes: no dedicated CVOT has been completed for retatrutide. This will likely be required for full regulatory characterisation.
• Rare events: uncommon adverse events (pancreatitis, thyroid signals, gallbladder events) require larger Phase 3 populations to characterise properly.
• Glucagon receptor long-term effects: sustained glucagon receptor agonism is novel in this context. Any unexpected hepatic, metabolic, or body composition effects may only emerge with longer exposure.[8][9]

The honest assessment: the Phase 2 safety profile appears manageable and broadly consistent with the GLP-1 agonist class, but the compound is genuinely novel (no triple agonist has been approved before), and caution is warranted until Phase 3 data is available.[1][4][11]

Half-Life

Retatrutide has a plasma half-life of approximately 6 days, enabling once-weekly subcutaneous administration. This is comparable to other modern incretin agonists:[7]

• Liraglutide: ~13 hours (daily injection)
• Semaglutide: ~7 days (weekly injection)
• Tirzepatide: ~5 days (weekly injection)
• Retatrutide: ~6 days (weekly injection)

The ~6-day half-life provides sustained receptor activation across all three targets (GLP-1, GIP, glucagon) throughout the dosing interval, maintaining the coordinated metabolic effects between weekly injections.[7]

TRIUMPH Phase 3 Programme

The TRIUMPH clinical programme represents the most ambitious development plan for any single incretin agonist, spanning multiple obesity-related indications:[6]

• TRIUMPH-1: obesity without diabetes
• TRIUMPH-2: obesity with type 2 diabetes
• TRIUMPH-3: obesity with obstructive sleep apnoea
• TRIUMPH-4: obesity with knee osteoarthritis

Giblin et al. (2026) published the rationale and design of the TRIUMPH registration programme in Diabetes, Obesity and Metabolism, detailing the Phase 3 trial structures that will generate the data necessary for FDA approval decisions.[6]

Timeline context: if Phase 3 results are positive, retatrutide could potentially reach FDA approval in 2027-2028, though regulatory timelines are inherently uncertain. The breadth of the TRIUMPH programme reflects Eli Lilly’s confidence in the compound based on Phase 2 results.

Limits of Current Evidence

• No approved indication. Retatrutide is investigational. All clinical data comes from Phase 2 trials (hundreds of participants, not thousands). Phase 3 is underway but not yet reported.[1][6]
• No long-term safety data beyond 48 weeks. The longest exposure in published trials is 48 weeks. Multi-year safety characterisation requires Phase 3 completion.[1][2]
• No cardiovascular outcome trial. Unlike semaglutide (SELECT) and liraglutide (LEADER), retatrutide has no completed CVOT. This is a significant evidence gap for a compound targeting cardiometabolic populations.
• Novel mechanism, unknown unknowns. No triple GLP-1/GIP/glucagon agonist has been approved before. Sustained glucagon receptor activation in combination with incretin agonism is pharmacologically unprecedented, and unexpected effects may emerge with larger populations and longer exposure.[7][8]
• Cross-trial comparisons are indirect. Retatrutide has not been compared head-to-head with tirzepatide or semaglutide in a single trial. The “24% vs 22% vs 17%” weight loss framing compares across different trials with different populations and designs.[1]
• Phase 2 results may not fully replicate. Phase 3 trials have stricter inclusion criteria, larger populations, and longer follow-up. Results sometimes differ from Phase 2.

Decision rule: retatrutide’s Phase 2 data is the strongest of any anti-obesity medication at this development stage, published in the highest-quality journals (NEJM, Lancet, Nature Medicine). But it remains investigational, and the evidence gap between “promising Phase 2” and “approved with long-term safety data” is substantial.

Verdict

Retatrutide represents the most ambitious evolution of the incretin agonist class — the first triple GLP-1/GIP/glucagon receptor agonist with clinical data. Its Phase 2 results (24.2% weight loss, 82.4% liver fat reduction, 2.0% HbA1c improvement) are the strongest ever reported for any single anti-obesity compound in controlled trials.[1][2][3]

The glucagon receptor component is the key differentiator. It introduces energy expenditure and hepatic fat oxidation mechanisms that go beyond appetite suppression, creating a “reduce intake + increase output” approach that may explain the superior weight loss magnitude compared to dual agonists like tirzepatide.[7][8]

The critical caveat: retatrutide is not yet approved, has no long-term safety data, and the Phase 3 TRIUMPH programme must confirm these results before clinical use can be evaluated. The compound’s position in this guide is as the most promising investigational candidate in the incretin class — extraordinary Phase 2 evidence, but still investigational. See Retatrutide vs Tirzepatide for the detailed positioning against the current best-in-class approved dual agonist.

For navigation, map this profile to Appetite & Weight Management, Fat Loss & Recomp, and Metabolic Health / Insulin Sensitivity. Cross-reference with Tirzepatide, Semaglutide, and Liraglutide for full class context.

FAQ

What is retatrutide?

Retatrutide (LY3437943) is a first-in-class investigational triple hormone receptor agonist that simultaneously activates GLP-1, GIP, and glucagon receptors. Developed by Eli Lilly, it produced the largest weight loss ever reported for any anti-obesity medication in Phase 2 trials (up to 24.2% at 48 weeks). It is currently in Phase 3 trials (TRIUMPH programme) but not yet FDA-approved.[1][6][7]

What does retatrutide do?

Retatrutide reduces appetite (via GLP-1/GIP receptors), improves glycaemic control (via GLP-1-mediated insulin secretion), and increases energy expenditure and fat oxidation (via glucagon receptor). Phase 2 trials demonstrated 24.2% body weight loss, 82.4% liver fat reduction, and HbA1c reductions of up to 2.0%.[1][2][3]

What are retatrutide side effects?

The most common side effects in Phase 2 trials were gastrointestinal: nausea, diarrhoea, vomiting, and constipation — consistent with the GLP-1 agonist class. These were generally mild to moderate and most common during dose escalation. Long-term safety data beyond 48 weeks is not yet available. Phase 3 will characterise rare events and the long-term effects of sustained glucagon receptor activation.[1][2]

Is retatrutide FDA approved?

No. Retatrutide is currently investigational and in Phase 3 clinical trials (the TRIUMPH programme). If Phase 3 results are positive, FDA approval could potentially occur around 2027-2028. It has not been approved for any indication in any country.[6]

How does retatrutide compare to tirzepatide?

Both are Eli Lilly compounds. Tirzepatide is a dual GIP/GLP-1 agonist (FDA-approved as Mounjaro/Zepbound); retatrutide adds a third target — the glucagon receptor. In cross-trial comparisons, retatrutide’s 24.2% weight loss exceeds tirzepatide’s ~20-22%, though no head-to-head trial exists yet. See Retatrutide vs Tirzepatide for the detailed comparison.[1][7]

How does retatrutide compare to semaglutide?

Semaglutide (Wegovy/Ozempic) is a single GLP-1 agonist producing ~15-17% weight loss. Retatrutide activates three receptors (GLP-1 + GIP + glucagon) and produced up to 24.2% weight loss in Phase 2. However, semaglutide is FDA-approved with extensive safety data including a cardiovascular outcomes trial (SELECT), while retatrutide remains investigational.[1]

Why is the glucagon receptor important?

Glucagon receptor activation increases hepatic fat oxidation, stimulates thermogenesis, and raises energy expenditure. This creates a “dual mechanism” for weight loss: GLP-1/GIP reduce caloric intake through appetite suppression, while glucagon increases caloric output through metabolic activation. This combination likely explains retatrutide’s superior weight loss and extraordinary liver fat reduction results.[3][7][8]

Retatrutide dose and retatrutide dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Retatrutide is an investigational compound not approved for any indication. Phase 2 trials evaluated doses from 0.5 mg to 12 mg weekly. This profile focuses on mechanism context, evidence quality, and risk-aware interpretation.

How much weight can you lose on retatrutide?

In the Phase 2 NEJM trial, the highest dose (12 mg weekly) produced 24.2% mean body weight loss at 48 weeks. 83% of participants lost ≥15% and 63% lost ≥20%. The weight loss trajectory was still descending at 48 weeks, suggesting even greater losses with longer treatment. These are Phase 2 results; Phase 3 will provide definitive efficacy data.[1]

Does retatrutide help with fatty liver?

Yes — the Phase 2a MASLD trial (Sanyal 2024, Nature Medicine) showed up to 82.4% liver fat reduction from baseline, with 93% of participants meeting the clinically meaningful ≥30% threshold. This is the strongest liver fat reduction data for any incretin-class compound, likely driven by the glucagon receptor component’s direct effects on hepatic fat oxidation.[3]

When will retatrutide be available?

Retatrutide is in Phase 3 clinical trials (TRIUMPH programme). If results are positive and regulatory submission proceeds smoothly, approval could potentially occur around 2027-2028. Regulatory timelines are inherently uncertain and depend on Phase 3 results, safety data, and regulatory review processes.[6]

Is retatrutide safe?

Phase 2 data shows a safety profile broadly consistent with the GLP-1 agonist class (primarily GI side effects). However, long-term safety data beyond 48 weeks is not yet available, and the glucagon receptor component is pharmacologically novel. Phase 3 trials with larger populations and longer follow-up will provide the definitive safety characterisation. Caution is warranted for any investigational compound without full regulatory review.[1][2][6]

References

1. Jastreboff AM, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315.
2. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. PMID: 37385280.
3. Sanyal AJ, et al. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024;30(8):2292-2300. PMID: 38858523.
4. Pasqualotto E, et al. Effects of once-weekly subcutaneous retatrutide on weight and metabolic markers: A systematic review and meta-analysis of randomized controlled trials. Metabol Open. 2024;24:100313. PMID: 39318607.
5. Coskun T, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2025;13(7):527-537. PMID: 40609566.
6. Giblin K, et al. Retatrutide for the treatment of obesity, obstructive sleep apnea and knee osteoarthritis: Rationale and design of the TRIUMPH registration programme. Diabetes Obes Metab. 2026;28(2):e70089. PMID: 41090431.
7. Coskun T, et al. LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept. Cell Metab. 2022;34(9):1234-1247.e9. PMID: 35985340.
8. Katsi V, et al. Retatrutide — A Game Changer in Obesity Pharmacotherapy. Biomolecules. 2025;15(7):935. PMID: 40563436.
9. Abdul-Rahman T, et al. The power of three: Retatrutide’s role in modern obesity and diabetes therapy. Eur J Pharmacol. 2024;984:177068. PMID: 39515565.
10. Abdrabou Abouelmagd A, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for obesity treatment: a systematic review and meta-analysis. Proc (Bayl Univ Med Cent). 2025;38(3):361-368. PMID: 40291085.
11. Kaur M, et al. A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity. Eur J Clin Pharmacol. 2024;80(5):621-632. PMID: 38367045.

Tirzepatide is a dual GIP/GLP-1 receptor agonist peptide developed by Eli Lilly and marketed under the brand name Mounjaro for type 2 diabetes management. It is the first approved dual incretin — activating both GIP and GLP-1 pathways simultaneously — which distinguishes it from single-pathway agents in the same therapeutic class.[1][2]

If your query is what is tirzepatide or what is Mounjaro, the practical answer is: a tirzepatide peptide analog — known commercially as tirzepatide Mounjaro — studied extensively in metabolic, body-weight, and glycaemic contexts, with some of the strongest modern trial coverage of any incretin-class compound. Under the brand name Mounjaro (Eli Lilly), tirzepatide received FDA approval for type 2 diabetes in 2022 and has since been evaluated across the SURMOUNT and SURPASS trial programmes for weight-related and cardiometabolic outcomes.[1][3][4]

The strongest interpretation model is trend-first: evaluate appetite behaviour, metabolic markers, and week-to-week adherence quality over time, not short one-day fluctuations. For direct peptide-level comparison context, see Tirzepatide vs Semaglutide and Tirzepatide vs Liraglutide.

Compound Profile

What Does Tirzepatide Actually Do?

Tirzepatide is typically interpreted through appetite, glycaemic, and weight-trend outcomes. As a dual incretin — sometimes called a twincretin — it engages both GIP and GLP-1 receptor signalling simultaneously, a mechanism distinct from single-pathway GLP-1 agonists like semaglutide or liraglutide.[2][5]

The practical question is whether satiety behaviour, metabolic control, and adherence quality improve consistently over multi-week blocks. Useful practical markers include:

• Appetite regulation trend: lower hunger pressure and improved portion-control consistency — the core Mounjaro weight loss mechanism.
• Metabolic-control trend: improved glucose-related markers in appropriate monitored contexts, relevant to Mounjaro clinical use in type 2 diabetes.
• Weight-trend stability: sustained directional body-weight change rather than volatile short-term swings — the primary tirzepatide weight loss signal.
• Adherence quality: improved ability to maintain structured nutrition and routine behaviours under reduced appetite burden.

Best interpreted as a metabolic-behaviour support framework over time, not a one-week transformation model.

How Tirzepatide Works

Understanding Mounjaro how does it work and how Mounjaro works starts with its dual-receptor mechanism. Tirzepatide simultaneously activates the GIP receptor and the GLP-1 receptor — two incretin pathways that regulate appetite signalling, insulin secretion, glucagon suppression, and downstream energy-balance behaviour.[2][5][6]

For those asking Mounjaro how it works, this dual action is what distinguishes Mounjaro from single-pathway GLP-1 receptor agonists. Research suggests the GIP component may contribute additive metabolic effects — including enhanced insulin sensitivity and potentially different effects on body composition — beyond what GLP-1 agonism alone provides.[5][6]

Tirzepatide is an imbalanced agonist: it shows stronger GIP-receptor activity relative to its GLP-1 activity, which may partially explain the differentiated clinical outcomes observed in head-to-head trials against semaglutide.[5][6] In practical interpretation, mechanism plausibility does not replace baseline discipline — outcomes still depend heavily on nutrition structure, activity pattern, sleep quality, and long-horizon consistency.

Appetite & Weight Management Context

In appetite-focused contexts, tirzepatide is evaluated by satiety stability and reduced drive to overeat. The SURMOUNT trial programme — the largest weight-focused dataset for any dual incretin — reported significant mean weight reductions across multiple populations and timeframes, making Mounjaro weight loss one of the most-studied outcomes in the incretin class.[1][3][4]

For tirzepatide weight loss intent, the responsible framing is trend-based and evidence-linked. SURMOUNT-1 reported mean weight reductions of up to 22.5% at 72 weeks in adults with obesity.[4] SURMOUNT-4 demonstrated that continued treatment maintained weight reduction versus placebo after an initial run-in period.[1] These are population-level averages — individual outcomes vary by baseline, adherence, and duration. The average weight loss on Mounjaro in trials should be interpreted as a statistical central tendency, not a guaranteed individual outcome.

The strongest practical signal is whether appetite becomes predictable enough to support steady decision-making across days and weeks — not whether one meal feels different. For comparison with other GLP-1 pathway agents, see Tirzepatide vs Semaglutide and Tirzepatide vs Liraglutide. For broader class context, see the Appetite & Weight Management goal page.

Fat Loss & Recomp Context

Body-composition relevance is usually mediated by appetite and adherence effects. When appetite pressure falls and routine quality improves, fat-loss and recomp trends can become more consistent over time. Recent body-composition analysis from SURMOUNT-1 indicates that tirzepatide-associated weight loss includes a meaningful proportion of fat mass reduction, though lean mass loss also occurs — consistent with most weight-loss interventions.[10]

For Mounjaro fat loss intent, the key distinction is between scale weight and composition. Trial-level data suggests the fat-to-lean mass loss ratio with tirzepatide is broadly comparable to other pharmacological weight-loss approaches, and may improve with concurrent resistance training — though this has not been directly tested in the SURMOUNT programme.

In this context, period-to-period consistency is generally more informative than daily scale noise. That is different from claiming immediate visual transformation — the practical signal is sustainable trajectory. For peptide-level recomposition context, see the Fat Loss & Recomp goal page.

Metabolic Health / Insulin Sensitivity Context

In metabolic contexts, tirzepatide is interpreted through glycaemic and insulin-related trend improvements within monitored frameworks. The SURPASS trial programme demonstrated significant HbA1c reductions in type 2 diabetes populations, with SURPASS-2 showing tirzepatide outperforming semaglutide 1 mg on glycaemic endpoints.[2][7]

As the flagship Eli Lilly weight loss drug, Mounjaro medication received FDA approval for type 2 diabetes management in 2022, and Mounjaro for type 2 diabetes remains its primary licensed indication. The dual GIP/GLP-1 mechanism is thought to provide complementary insulin-sensitising effects beyond what GLP-1 agonism alone achieves — though the precise contribution of GIP-receptor activation to metabolic outcomes is still being characterised.[5][6]

The key practical lens is stability: does metabolic control become more consistent over time while lifestyle fundamentals remain structured? Recent data also suggests tirzepatide may have cardiovascular relevance — the SURPASS-CVOT programme and a pre-specified cardiovascular event meta-analysis support a neutral-to-beneficial cardiovascular signal, though dedicated outcomes trials are ongoing.[8] For metabolic context across peptides, see the Metabolic Health / Insulin Sensitivity goal page.

Tirzepatide Benefits

Based on the available clinical evidence, the following tirzepatide benefits are supported at moderate-to-high confidence:

• Appetite-control consistency: meaningful and sustained reduction in hunger pressure across structured routines — the primary driver of Mounjaro weight loss outcomes.
• Weight-trend outcomes: among the strongest trial-supported weight reductions in the incretin class, with SURMOUNT-1 reporting up to 22.5% mean reduction at 72 weeks.[4]
• Glycaemic-control support: significant HbA1c improvement in type 2 diabetes populations, outperforming comparator agents in SURPASS head-to-head trials.[2][7]
• Adherence potential: once-weekly administration and reduced hunger burden may support better long-horizon adherence compared to daily-administration alternatives.
• Cardiometabolic signals: neutral-to-beneficial cardiovascular risk profile based on pre-specified meta-analysis data, with dedicated outcomes trials underway.[8]
• Sleep apnoea context: recent trial data (SURMOUNT-OSA) suggests tirzepatide may reduce obstructive sleep apnoea severity in the context of weight reduction.[9]

Evidence-weighted read: benefits are substantial in trial settings, but real-world results remain baseline-dependent and should be interpreted conservatively.

Tirzepatide Side Effects

For tirzepatide side effects and Mounjaro side effects intent, the most commonly reported adverse events are gastrointestinal, particularly during dose-escalation phases. The side effects of Mounjaro in clinical trials include:[1][2][4][7]

• Nausea: the most frequently reported side effect, typically transient and dose-dependent.
• Diarrhoea: Mounjaro diarrhoea (also searched as Mounjaro diarrhea) is reported across trials, sometimes persisting beyond the escalation window. Management approaches vary by clinical context.
• Vomiting: less common than nausea but reported at higher dose levels.
• Constipation: GI motility shifts can produce either diarrhoea or constipation depending on individual response.
• Appetite suppression: may feel excessive in some contexts, leading to reduced caloric intake below intended targets.
• Stomach cramps and heartburn: Mounjaro stomach cramps and reported by some participants, particularly during early treatment phases.
• Fatigue: some participants report reduced energy during escalation, which typically resolves.

For tirzepatide long term side effects context: the SURMOUNT-4 extension data provides 88-week safety information, with no new safety signals emerging beyond those identified in shorter trials.[1] However, long-horizon post-marketing surveillance is ongoing. Interpretation should be trend-aware and medically supervised in clinical contexts.

Half-Life

Tirzepatide has an elimination half-life of approximately 5 days (~120 hours), supporting its once-weekly clinical use pattern.[2][7] This extended half-life is achieved through structural modifications including a C20 fatty diacid moiety that promotes albumin binding and slows clearance.

Practical takeaway: evaluate outcomes via week-level trajectory and tolerance trends rather than one-day timing assumptions. The multi-day half-life means steady-state concentrations are typically reached after approximately 4-5 weekly administrations, which is why clinical trials use dose-escalation schedules spanning several weeks.

Limits of Current Evidence

• Evidence is stronger than many peptide categories — multiple Phase III programmes (SURPASS, SURMOUNT) with large sample sizes and active comparators — but not all populations respond equally.
• Tolerance and GI-related persistence can materially affect real-world outcomes versus trial conditions.
• Short observation windows can overstate or understate long-horizon effects; SURMOUNT-4 withdrawal data suggests weight regain after discontinuation.[1]
• Head-to-head data versus semaglutide exists for T2D (SURPASS-2) but direct weight-loss comparison data is limited to retrospective analyses.[2][11]
• Body composition data (fat vs lean mass loss) is emerging but not yet comprehensive across all dose levels.[10]
• Cardiovascular outcomes trials are ongoing — current data is from meta-analysis, not dedicated CVOT.[8]
• Comparisons with newer triple agonists like retatrutide are limited to early-phase data; see Retatrutide vs Tirzepatide for current context.

Verdict

Tirzepatide — marketed as Eli Lilly Mounjaro — is best interpreted as a high-evidence metabolic and appetite-regulation compound with the strongest weight-related trial data in the dual incretin class. Its dual GIP/GLP-1 mechanism provides a differentiated approach compared to single-pathway GLP-1 agonists.

It is most useful when paired with structured routine fundamentals and conservative, monitored interpretation of both efficacy and tolerability trends. The Mounjaro evidence base is extensive and growing, but outcomes remain individually variable and should be evaluated over multi-week horizons rather than short-term snapshots.

FAQ

Tirzepatide dose and Tirzepatide dosage: why not listed here?

This page is informational only and does not provide dosing protocols. Dose and dosage intent is valid, but this profile focuses on mechanism context, evidence quality, and risk-aware interpretation. For clinical dosing information, consult the prescribing information or a qualified healthcare provider.

What is the difference between Tirzepatide and Mounjaro?

The tirzepatide brand name most people recognise is Mounjaro. Tirzepatide is the active compound; Mounjaro is the brand name under which Eli Lilly markets tirzepatide for type 2 diabetes. Zepbound is a separate brand name for tirzepatide approved specifically for chronic weight management. The underlying molecule is identical.

Tirzepatide vs Semaglutide: what is the practical difference?

Both are incretin-pathway therapies, but tirzepatide is a dual GIP/GLP-1 agonist whereas semaglutide targets GLP-1 only. Head-to-head trial data (SURPASS-2) showed tirzepatide achieving greater HbA1c reductions versus semaglutide 1 mg in type 2 diabetes.[2] For weight outcomes, retrospective analyses suggest tirzepatide may produce greater mean weight loss, though direct randomised weight-focused comparisons are limited.[11] See Tirzepatide vs Semaglutide for full context.

How does Mounjaro work for weight loss?

Mounjaro (tirzepatide) works primarily through dual GIP and GLP-1 receptor agonism, which reduces appetite, slows gastric emptying, and improves insulin sensitivity. As a Mounjaro GLP-1 (Mounjaro GLP 1) and GIP dual agonist, the combined effect supports sustained caloric deficit through reduced hunger pressure. In the SURMOUNT-1 trial, participants achieved mean weight reductions of 15-22.5% at 72 weeks depending on dose.[4]

What are the most common Mounjaro side effects?

The most commonly reported side effects of Mounjaro are gastrointestinal: nausea, diarrhoea, vomiting, constipation, and reduced appetite. These typically peak during dose-escalation phases and improve with continued use. Stomach cramps, heartburn, and fatigue are also reported. Serious adverse events are uncommon in trial data.[1][2][4]

Is Mounjaro a GLP-1 drug?

Mounjaro includes GLP-1 receptor agonism but is technically a dual incretin — a GIP and GLP-1 receptor agonist. This distinguishes it from pure GLP-1 agonists like semaglutide (Ozempic/Wegovy) and liraglutide (Victoza/Saxenda). The dual mechanism is why tirzepatide is sometimes called a “twincretin.”

What happens when you stop taking Mounjaro?

SURMOUNT-4 data shows that participants who discontinued tirzepatide after an initial treatment period experienced significant weight regain compared to those who continued treatment.[1] This is consistent with the pattern observed across incretin-class therapies and highlights the importance of sustained lifestyle modification alongside any pharmacological intervention.

Who makes Mounjaro?

Mounjaro is developed and manufactured by Eli Lilly and Company. It was approved by the FDA for type 2 diabetes in May 2022. The same compound, tirzepatide, is also marketed as Zepbound for chronic weight management.

Can Mounjaro help with sleep apnoea?

Recent trial data from the SURMOUNT-OSA programme suggests tirzepatide may reduce obstructive sleep apnoea severity in the context of weight reduction.[9] However, this is an emerging area of research and tirzepatide is not currently approved for sleep apnoea treatment.

How should tirzepatide weight loss claims be interpreted?

Use trend-level, evidence-weighted framing. Strong outcomes are reported in trials — SURMOUNT-1 showed up to 22.5% mean body-weight reduction at 72 weeks.[4] But real-world results remain dependent on adherence, tolerance, duration, and baseline context. Average weight loss on Mounjaro in trials represents population means, not individual guarantees.

References

1. Jastreboff AM, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38-48. PMID: 38078870. PubMed.
2. Del Prato S, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes (SURPASS-2). N Engl J Med. 2021;385(6):503-515. PMID: 34170647. PubMed.
3. Garvey WT, et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2). Lancet. 2023;402(10402):613-626. PMID: 37385275. PubMed.
4. Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024. PubMed.
5. Willard FS, et al. Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist. JCI Insight. 2020;5(17):e140532. PMID: 32730231. PubMed.
6. Coskun T, et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. Mol Metab. 2018;18:3-14. PMID: 30473097. PubMed.
7. Frias JP, et al. Efficacy and safety of tirzepatide monotherapy versus placebo in type 2 diabetes (SURPASS-1). Lancet. 2021;398(10295):143-155. PMID: 34186022. PubMed.
8. Sattar N, et al. Tirzepatide cardiovascular event risk assessment: a pre-specified meta-analysis. Nat Med. 2022;28(3):591-598. PMID: 35210595. PubMed.
9. Malhotra A, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. N Engl J Med. 2024;391(14):1319-1330. PMID: 38912654. PubMed.
10. Abildgaard J, et al. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study. Diabetes Obes Metab. 2025;27(5):2447-2456. PMID: 39996356. PubMed.
11. Rodriguez PJ, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. PMID: 38976257. PubMed.